

Phase –II Timetable for MBBS Course (Batch 2022-23)

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 1	Mon	18-Dec-23	Surg L-1 SU 8.1: Ethics in General Surgery	Clinical Posting			Lunch	Micro L-1 MI 1.3: Infectious disease: Epidemiology	Micro SGL-1 & 2 MI 1.2: [AB] Gram Staining ZN Staining & Stool routine Microscopy; FMT SGL-1&2 [CD]: FM 2.17, 2.18: Crime scene investigation & Exhumation	
	Tue	19-Dec-23	Path L-1 PA1.1-1.3: Introduction to Pathology	Clinical Posting			Lunch	Micro L-2 MI 1.1: Introduction to Microbiology & Infectious agents & detection	Path L-2 PA2.4a Cell injury cell death-Types, mechanisms	Pharm L-1 PH 1.5(I) Pharmacodyn amics-1
	Wed	20-Dec-23	Med L-1 IM 26.1-26.4, 26.11- 26.13, 13.4: Clinical Medicine & Health Problems in India	Clinical Posting			Lunch	Pharm L-2 PH1.1(a): Principles of Pharmacology	Path SGL-1 & 2 PA.1.1: Intro to Pathology [AB]; Pharm SGL 1&2, PH 2.1: Intro to Pharmacology, Dosage forms [CD]	
	Thu	21-Dec-23	Com Med L-1 CM 3.5: Housing & Health	Clinical Posting			Lunch	Path L-3 PA2.7,2.4b: Cellular aging and apoptosis (VI-PY)	Path SGL-2 & 3 PA.1.1: Intro to Pathology[CD]; Pharm SGL-2 &3, PH 2.1: Intro to Pharmacology, Dosage forms[AB]	
	Fri	22-Dec-23	O&G L-1 OG 2.1:Applied Anatomy. Anterior abdominal wall , pelvic floor , supports of uterus, bladder & ureter surgical importance. Avascular spaces of pelvis [VI-AN]	Clinical Posting			Lunch	FMT L-1 FM 1.1,1.2: Introduction & History of FM	Micro SGL-3&4 MI 1.2 [CD]: Gram Staining ZN Staining & Stool routine Microscopy [VI- AN]; FMT SGL-3&4 [AB] FM 2.17, 2.18: Crime scene investigation & Exhumation	
	Sat	23-Dec-23	Pharm L-3 PH1.5(I) Pharmacodynamics -2	AETCOM -1; Module 2.1: The foundations of communication - 2 Introductory small group session (Whole Batch) Pathology Dept.	PN-1, Module 2.1 Infection Control Practices- Part II Interactive discussion (Whole Batch) Microbiology Dept.	PN-2 Module 2.1 InfectionContro l Practices- Part II Small Group case discussion Microbiology Dept.	Lunch	Path L-4 PA 28.16 Urothelial tumors	Sports & Extra-Curricular Activities	
	SUNDAY									

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 2			Christmas Day Mon 25 Dec 2023							
	Tue	26-Dec-23	Path L-5 PA4.2 Mediators of acute inflammation	Clinical Posting			Lunch	Micro L-3 Sterilization & Disinfection -1 MI 1.5	Path L-6 PA4.3 Chronic inflammation including causes, types	Pharm L-4 PH1.5(II): Pharmacodynamics-3
	Wed	27-Dec-23	Med L-2 Fever Introduction to Clinical Medicine-1 (IM 4.1- 4.5)	Clinical Posting			Lunch	Pharm L-5 PH1.1(b): Principles of pharmacotherapeutics	Path SGL 5&6 (AB)PA.1.1 Techniques in surgical Pathology; Pharm SGL5&6 (CD) PH1.11: Routes of drug administration	
	Thu	28-Dec-23	Com Med L-2 Disposal of human excreta and sewage CM 3.4	Clinical Posting			Lunch	Path L-7 PA-13.1 Describe haematopoiesis & extramedullary haematopoiesis	Path SGL 7&8 (CD)PA.1.1 Techniques in surgical Pathology; Pharm SGL7 &8 (AB) PH1.11: Routes of drug administration	
	Fri	29-Dec-23	O&G L-2 Development of Female Genital Tract OG 2.1[VI-AN]	Clinical Posting			Lunch	FMT L-2 (FM 1.3)Legal procedures- 1 IPC, CrPC, IEA, Inquest, Offences	Micro SGL5&6 (AB) Gram Staining ZN Staining & Stool routine Microscopy MI 1.2[VI-AN];FMT SGL 5&6 [CD], FM 5.3 For Psy-IV: Civil Responsibility	
	Sat	30-Dec-23	Pharm L-6 PH1.5(II):Pharmacodynamics-4	AETCOM -2; Module 2.1: Foundations of communication - 2 -Focused small group session (Group A, audience Group B) Pathology Dept.	AETCOM -3; Module 2.1: Foundations of communication - 2 -Focused small group session (Group B, audience Group A) Pathology Dept.	PN-4, Module 2.1 Infection Control Practices- Part II- Debriefing and Feedback (Whole Batch) Microbiology Dept	Lunch	Path L-8 PA 28.4 Kidney – CRF	Sports & Extra-Curricular Activities	
				SUNDAY						

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 3	Mon	1-Jan-24	Surg L-2 SU8.2: Professionalism & empathy to the patient undergoing General Surgery	Clinical Posting			Lunch	Micro L-4 Sterilization & Disinfection -2 MI 1.4	Micro SGL7&8 (AB) Gram Staining ZN Staining & Stool routine Microscopy MI 1.2 [VI-AN]);; FMTSGL-7&8 [CD] FM 5.3 For Psy-IV: Civil Responsibility	
	Tue	2-Jan-24	Path L-9 PA13.3,13.4,14.1, 14.2: Haematology Anemia- Intro, Iron deficiency anemia							
	Wed	3-Jan-24	Med L-3 Fever Introduction-2 (IM 4.10,4.11,4.12)	Clinical Posting			Lunch	Pharm L-8 PH(1.4)(II) Pharmacokinetics	Path SGL 9&10 (AB) PA.1.1 Microscope; Pharm SGL 9&10 (CD) PH1.6&1.7 Pharmacovigilance & related activity	
	Thu	4-Jan-24	Com Med L-3 Medical entomology CM3.7	Clinical Posting			Lunch	Path L-11 PA15.1-15.4 Haematology - Macrocytic anemia	Path SGL11&12 (CD) PA.1.1 Microscope; Pharm SGL 11&12 (AB) PH1.6&1.7 Pharmacovigilance & related activity	
	Fri	5-Jan-24	O&G L-3 Physiology of Menstruation & Ovulation OG 3.1 [VI-AN]	Clinical Posting			Lunch	FMT L-3 (FM 1.7,1.8) Legal procedures- IV Dying dec., Dying dep., Latest amendments	Micro SGL9&10:(AB)Gram Staining ZN Staining & Stool routine Microscopy MI 1.2 (DOAP); FMT SGL9&10(CD) FM14.18: Prepare MLR in police/judicial custody; FM14.22: Recording of evidence	
	Sat	6-Jan-24	Pharm L-9 PH1.5(II) Pharmacodynamics-6	AETCOM -2; Module 2.1: Foundations of communication - 2 -Focused small group session (Group A, audience Group B) Pathology Dept.	AETCOM -3; Module 2.1: Foundations of communication - 2 -Focused small group session (Group B, audience Group A) Pathology Dept.	Mentor-Mentee Interaction		Lunch	Path L-12 PA 31.2: Carcinoma Breast [VI-AN]	Sports & Extra-Curricular Activities
SUNDAY										

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm	
Week 4	Mon	8-Jan-24	Surg L- 3 SU18.2: Skin tumors & their management [VI-AN].	Clinical Posting				Lunch	Micro L-6 Drug Resistance & Antibiotics (MI 1.6)	Micro SGL11&12:(CD)Gram Staining ZN Staining & Stool routine Microscopy MI 1.2; FMT SGL11&12 (AB) FM14.18: Prepare MLR in police/judicial custody; FM14.22: Recording of evidence	
	Tue	9-Jan-24	Path L-13 PA6.4:Hemodynamics Normal haemostasis	Clinical Posting				Lunch	Micro L-7 Immune Response (MI 1.8)	Path L-14 PA16.1-16.3a Haematology - Hemolytic anemia- Introduction, Thalassemia	Pharm L-10 PH1.5(V) Pharmacodynamics
	Wed	10-Jan-24	Med L-4 PUO (IM 4.8)	Clinical Posting				Lunch	Pharm L-11 PH(1.4)(III) Pharmacokinetics (2)	Path SGL 13&14: (AB) PA - DOAP – 13.2: Sample collection and Role of anticoagulants; Pharm SGL-13&14 (CD) PH1.10&3.1: Prescription writing related to communications to Pts	
	Thu	11-Jan-24	Com Med L-4 Medical entomology CM 3.7	Clinical Posting				Lunch	Path L-15 PA4.3 b: Granulomatous inflammation	Path SGL-15&16: (CD) PA - DOAP – 13.2 Sample collection and Role of anticoagulants; Pharm SGL-15&16 (AB) PH1.10&3.1: Prescription writing related to communications to Pts	
	Fri	12-Jan-24	O&G L-4 Gametogenesis, fertilization, implantation . OG 3.1 [VI-AN]	Clinical Posting				Lunch	FMT L-4 (FM2.1, 2.2,2.5, 2.6, 2.7): Death, Modes of death, Presumption of death & survivorship, Suspended animation	Micro SGL-13&14:(AB) Stool Examination MI 1.2; FMT SGL-13&14 [CD]: (FM14.18) FM 1.5,1.6 Legal procedures- III; Court procedures & Witness, perjury	
	Sat	13-Jan-24	Pharm L-12 PH1.5(IV) Pharmacodynamics	AETCOM-4; Module 2.1: Foundations of communication - 2 -Skills lab session (Whole Batch) Pathology Dept.	PN-6, Module 2.2 Emergence & Re-emergence of microbes Self-Study, SGD (Batch in 2: Group A, Audience Group B) Com Med. Dept.	PN-7, Module 2.2 Emergence & Re-emergence of microbes Self-Study,SGD(Batch in 2: Group B, Audience Group A) CM Dept.		Lunch	Path L-16 PA28.16 Urothelial tumors [VI-AN]	Sports & Extra-Curricular Activities	
				SUNDAY							

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm	
Week 5	Mon	15-Jan-24	Surg L-4 SU5.2: Wounds.	Clinical Posting				Lunch	Micro L-8 Immunological Mechanism MI 1.7	Micro SGL-15&16:(CD) Stool Examination MI 1.2 (DOAP); FMT SGL-15&16 (AB) FM 1.5, 1.6 Legal procedures- III; Court procedures & Witness, perjury	
	Tue	16-Jan-24	Path L-17 PA 16.3b Haematology – Sickle cell anemia [VI-PY]	Clinical Posting				Lunch	Micro L-9 Antigen Antibody Reaction MI1.10	Path L-18 PA5.1 a: Healing and repair	Pharm L-13 PH 1.13(a): Adrenergic drugs
	Wed	17-Jan-24	Med L-5 Investigation Non Invasive (IM 4.12, 4.18, 5.13, 6.11, 6.12)	Clinical Posting				Lunch	Pharm L-14 PH(1.4)(VI) Pharmacokinetics	Path SGL 17 &18 (AB) PA– 8.3:Cytopathology techniques & interpretation; Pharm SGL- 17&18: (CD) PH2.2: ORS Preparation	
	Thu	18-Jan-24	Com Med L-5 Insecticides and rodenticides CM3.8	Clinical Posting				Lunch	Path L-19 PA 6.1: Hemodynamic - Fluid &electrolyte balance, describe edema, its types	Path SGL 19&20: (CD) PA – 8.3 Cytopathology techniques & interpretation; Pharm SGL 19&20: (AB) PH2.2: ORS Preparation DOAP	
	Fri	19-Jan-24	O&G L-5 Embryology of fetus & its growth . Development , anatomy and physiology of placenta OG 4.1 [VI-AN]	Clinical Posting				Lunch	FMT L-5 (FM 2.8) Algormortis, Livormortis, Rigormortis, cadaveric Spasm	Micro SGL 17&18: (AB) Gram Staining ZN Staining & Stool routine Microscopy MI 1.2 (DOAP);FMT SGL 17&18: [CD](FM 2.15) NHRC Guidelines for autopsy case of in death in Custody	
	Sat	20-Jan-24	Pharm L-15 PH1.64(a): Drug development including phase of clin. Trials	AETCOM -5; Module 2.1: Foundations of communication - 2 -Discussion and closure (Whole Batch) Pathology Dept.	PN-8 Module 2.2 Emergence and Re-emergence of microbes Small Group discussion (Whole Batch) Com Med. Dept.	PN-11, Module 2.3 Diagnostic tools Exploratory & interactive theory session (Whole Batch) Microbiology Dept.		Lunch	Path L-20 PA. 2.2, 2.3,2.4 Cell Injury and Adaptation [VI-PY]	Sports & Extra-Curricular Activities	
	SUNDAY										

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm	
Week 6	Mon	22-Jan-24	Surg L-5 SU27.7: Lymph edema, and Lymphomas [VI-AN]	Clinical Posting				Lunch	Micro L-10 Immunodeficiency disease MI 1.10	Micro SGL 19&20: (CD) Gram Staining ZN Staining & Stool routine Microscopy MI 1.2 (DOAP);FMT SGL 19&20 [AB];FM 2.15) NHRC Guidelines for autopsy case of in death in Custody	
	Tue	23-Jan-24	Path L-21 PA 9.1: Immunity – Principles and mechanism [HI-MI]	Clinical Posting				Lunch	Micro L-11 Sterilization and Disinfection MI 1.5	Path L-22 PA 17.1, 17.2 Haematology- Aplastic anemia	Pharm L-16 PH 1.13(a)II Adrenergic drugs
	Wed	24-Jan-24	Med L-6 Investigation Invasive (IM 4.12, 4.13, 4.14, 4.15, 4.16, 5.15, 6.15, 7.16, 8.13)	Clinical Posting				Lunch	Pharm L-17 PH1.5(VI) Pharmacodynamics	Path SGL-21&22:(AB) PA – 8.3: Cytopathology techniques and interpretation; Pharm SGL-21&22: (CD) PH3.2 Prescription audit	
	Thu	25-Jan-24	Com Med L-6 Introduction to demography & world population trends CM-9.1	Clinical Posting				Lunch	Path L-23 PA 9.2 Immunity – hypersensitivity reactions	Path SGL-23&24 (CD) PA – 8.3: Cytopathology techniques and interpretation; Pharm SGL-23&24:(AB) PH3.2 Prescription audit	
			Republic Day: Fri, 26 Jan 2024								
	Sat	27-Jan-24	Pharm L-18 PH1.8 Drug interactions	PN-9, Module 2.2 Emergence and Re-emergence of microbes Plenary & Closure (Whole Batch) Com Med. Dept.	PN-10, Module 2.2 Emergence and Re-emergence of microbes Plenary & Closure (Whole Batch) Com Med. Dept.	Mentor-Mentee Interaction			Path L-24 PA.2.1 : Cell Injury and Adaptation	Sports & Extra-Curricular Activities	
			SUNDAY								

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 7	Mon	29-Jan-24	Surg L-6 SU28.1: Hernias [VI-AN]	Clinical Posting			Lunch	Micro L-12 Autoimmunity MI 1.10: Transplant & Cancer Immunology MI 1.11	Micro SGL-21&22:(AB) Stool Examination MI 1.2;FMT SGL-21&22(CD) FM 3.2 Footprints, Scars, tattoo marks, superimposition, etc.	
	Tue	30-Jan-24	PathL-25 PA 9.3: HLA system – Immune mechanism in transplant and transplant rejection	Clinical Posting			Lunch	Micro L-13 Hypersensitivity MI 1.10	Path L-26 PA 18.2a Myeloid leukemia	Pharm L-19 PH1.5(VII) Pharmacodynamics
	Wed	31-Jan-24	Med L-7 Critical care Management -1 (IM 1.4, 1.5, 1.7, 2.19, 3.17, 4.7,10.1,10.2,11.17,27.5, 27.19,27.21)	Clinical Posting			Lunch	Pharm L-20 PH 1.13(a)III Adrenergic drugs	Path SGL-25&26: (AB) PA DOAP–2.8 a Identify and describe various forms of cell injuries; Pharm SGL-25&26: (CD) PH3.2:Prescription audit	
	Thu	1-Feb-24	Com Med L-7 Population trends in India CM-9.3,9.4	Clinical Posting			Lunch	Path L-27 PA– 9.1: Principles and mechanisms involved in immunity mechanism [HI-MI]	Path SGL-27&28: (CD) PA –2.8 b DOAP Identify & describe various forms of cell injuries; Pharm SGL-27&28: (AB) PH3.2:Prescription audit	
	Fri	2-Feb-24	O&G L-6 Maternal high risk factors and verify immunological status OG 5.1	Clinical Posting			Lunch	FMT SDL -1 FM 5.3: For Psy:VIII Mental healthcare Act	Micro SGL-23&24(CD) Stool Examination MI 1.2 (DOAP) FMT SGL 23&24 [AB] FM 3.2 Footprints, Scars, tattoo marks, superimposition, etc.	
	Sat	3-Feb-24	Pharm L-21 PH 1.59(a) Essential Medicine	AETCOM -6; Module 2.2: The foundations of bioethics Large Group Session (Whole Batch) FMT Dept.	AETCOM -7; Module 2.2: The foundations of bioethics Large Group Session (Whole Batch) FMT Dept.	PN-12, Module 2.3 Diagnostic tools: Sample collection demo and hands on in skill lab; (Whole Batch) Microbiology Dept.	Lunch	Path L-28 PA 9.6: HIV and AIDS mechanism [VI-IM]	Sports & Extra-Curricular Activities	

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm	
SUNDAY											
Week 8	Mon	5-Feb-24	Surg L-7 SU30.1: Phimosis, paraphimosis and carcinoma penis. mechanism [VI-AN]				Clinical Posting	Lunch	Micro L-14 Anemia MI 2.4 (AITO)	Micro SGL-25&26:(AB) Gram Staining ZN Staining & Stool routine Microscopy MI 1.2 (DOAP);FMT 25&26 [CD]; FM: 2.12: Legal requirements for autopsy; Obscure autopsy, negative autopsy	
	Tue	6-Feb-24	Path L-29 PA 18.2 b: Hematology – Lymphoid leukemia [VI-PY]				Clinical Posting	Lunch	Micro L-15 Rheumatic fever & Diagnosis MI 2.1	Path L-30 PA 11.1: Cytogenetic abnormalities and mutations	Pharm L-22 PH1.14(a): Cholinergic drugs
	Wed	7-Feb-24	Med L-8 Critical care Management -2 (IM 1.4, 1.5, 1.7, 2.19,3.17,4.7, 10.1, 10.2,11.17,27.5, 27.19, 27.21)				Clinical Posting	Lunch	Pharm SDL-1 PH 3.3: Evaluation of drug Promotional Literature	Path SGL-29&30: (AB) PA– 4.4 (acute and chronic inflammation in gross and microscopic specimens) - DOAP; Pharm SGL- 29&30: (CD) PH3.4: Recognize ADR & report	
	Thu	8-Feb-24	Com Med L-8 Fertility CM 9.2				Clinical Posting	Lunch	Path L-31 PA.13.1, 13.3, 13.4 Introduction to haematology	Path SGL-31&32: (CD) PA– 4.4 (acute and chronic inflammation in gross and microscopic specimens) - DOAP; Pharm SGL-31&32: (AB) PH3.4 Recognize ADR & report	
	Fri	9-Feb-24	O&G L-8 Pregnancy- presentation; Pregnancy tests. OG 6.1 [VI-AN]				Clinical Posting	Lunch	FMT L-6 (2.9, 2.10) Putrefaction, Mummification, Maceration, Adipocere Time since death	Micro SGL-27&28: (CD) Gram Staining ZN Staining & Stool routine Microscopy MI 1.2 (DOAP); FMT SGL-27&28 (AB) FM 2.12: Legal requirements for autopsy; Obscure autopsy, negative autopsy	
	Sat	10-Feb-24	Pharm L-23 PH 1.7 ADR	AETCOM -8; Module 2.3: Health care as a right Participatory Student Seminar (Whole Batch) FMT Dept.	AETCOM -9; Module 2.3: Health care as a right Participatory Student Seminar (Whole Batch) FMT Dept.	PN-13, Module 2.3 Diagnostic tools Visit to laboratory Microbiology Dept.		Lunch	Path L-32 PA 11.2: Tumor and tumor like conditions in infancy and childhood	Sports & Extra-Curricular Activities	
	SUNDAY										

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 9	Mon	12-Feb-24	Surg L-8 SU30.2:Undescended testis [VI-AN]	Clinical Posting			Lunch	Micro L-16 Rheumatic fever: MI 2.1 [HI-PA]	Micro SGL-29&30: (AB) Diagnostic methods in Rheumatic fever (P) MI 2.3; FMT SGL-29&30: (CD) (FM 2.15): NHRC Guidelines for autopsy case of in death in Custody	
	Tue	13-Feb-24	Path L-33 PA 3.1: Amyloidosis	Clinical Posting			Lunch	Micro L-17 Filariasis: MI 2.5 [VI-IM]	Path L-34 PA 19.4a: Non-Hodgkin's lymphoma	Pharm L-24 PH1.16: a. Autacoids- I Histamine & antihistamine
	Wed	14-Feb-24	Med L-9 Critical care Management -3 (IM 1.4, 1.5, 1.7, 2.19, 3.17, 4.7, 10.1, 10.2, 11.17, 27.5, 27.19,27.21)	Clinical Posting			Lunch	Pharm L-25 PH1.16: b. Autacoids- I Histamine & antihistamine	Path SGL-33&34 (AB) PA -2.8 b DOAP Identify and describe various forms of cell injuries; Pharm SGL-33&34 (CD): Cholinergic & Anti-Cholinergic drugs	
	Thu	15-Feb-24	Com Med L-9 Introduction to epidemiology and descriptive epidemiology CM 7.5	Clinical Posting			Lunch	Path L-35 PA 20.1a Plasma cell myeloma [VI-IM]	Path SGL-35 &36 (CD) PA -2.8 b DOAP Identify and describe various forms of cell injuries; Pharm SGL-35&36(AB): Cholinergic & Anti-Cholinergic drugs	
	Fri	16-Feb-24	O&G L-9 Changes in the genital tract, CVS, respiratory, haematology, renal and GIT system in pregnancy OG 7.1	Clinical Posting			Lunch	FMT SDL-2 FM 1.5, 1.6 Legal procedures- III Court procedures & Witness, perjury	Micro SGL-31&32: (CD) Diagnostic methods in Rheumatic fever (P) MI 2.3 (DOAP);FMT SGL-31&32 (AB) (FM 2.15): NHRC Guidelines for autopsy case of in death in Custody	
	Sat	17-Feb-24	Pharm L-26 PH1.16: c. Autacoids- I Histamine & antihistamine	PN-17, Module 2.4 Vaccination strategies & Implementation Exploratory and interactive theory session (Whole Batch) Com Med. Dept.	PN-14, Module 2.3 Diagnostic tools SGD on Test Reports (Group A) Microbiology Dept.	PN-15, Module 2.3 Diagnostic tools Small Group Discussion on Test Reports (Group B) Microbiology Dept..	Lunch	Path L-36 PA 10.1: Malaria [VI-CM,IM]	Sports & Extra-Curricular Activities	
	SUNDAY									

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 10	Mon	19-Feb-24	Surg L-9 SU30.6 Tumours of testis	Clinical Posting			Lunch	Micro L-18 Rheumatic fever MI 2.1	Micro SGL-33&34: (AB) Diagnostic method in infective endocarditis MI 2.3;FMT SGL-33&34: (FM2.5,-2.7): Sudden death & THOTA	
	Tue	20-Feb-24	Path L-37 PA 19.4b: Hodgkin's disease [VI-IM]					Clinical Posting		
	Wed	21-Feb-24	Med L-10 Management of Infectious disease (IM 25.1-25.7, 25.12, 25.13)	Clinical Posting			Lunch			
	Thu	22-Feb-24	Com Med L-10 National Population policy CM-9.6					Clinical Posting		
	Fri	23-Feb-24	O&G L-10 ANC, assessment of period of gestation; screening for high-risk factors &Teratogenicity OG 8.1 & 4.1B	Clinical Posting			Lunch			
	Sat	24-Feb-24	Pharm L-28 PH 1.13(a)IV Adrenergic drugs					PN-18, Module 2.4 Vaccination strategies & Implementation Small Group Discussion (Group A: Vaccines in Disease Control) Com Med. Dept.	PN-19, Module 2.4 Vaccination strategies & Implementation Small Group Discussion (Group B: Vaccine Development Process) Biochem. Dept.	PN-16, Module 2.3 Diagnostic tools Discussion and closure (Whole Batch) Microbiology Dept.
	SUNDAY									

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 11	Mon	26-Feb-24	Surg L-10 SU30.4: Varicocele	Clinical Posting			Lunch	Micro L-20 HIV MI 2.7 [VI-IM]	Micro SGL-37&38: (AB) Diagnostic method in infective endocarditis MI 2.3;FMT SGL-37&38: (CD) (FM5.1) For Psy-I: Intro+ Classification, PTSD	
	Tue	27-Feb-24	Path L-41 PA 21.2a: Vascular and platelet disorders including ITP	Clinical Posting			Lunch	Micro L-21 Kala-azar: MI 2.5 [VI-IM,CM]	Path L-42 PA 11.3b: Common storage disorders in infancy and childhood	Pharma SDL-3 PH1.60(a): Pharmacogenomics
	Wed	28-Feb-24	Med L-11 Systemic Infections by Gram +ve Bacteria (IM 4.3, 4.12,4.16) [VI-MI]	Clinical Posting			Lunch	Pharm L-29 PH 1.16 Autacoids- I II	Path SGL 41 &42: (AB) PA-3.2 DOAP (Amyloidosis); Pharm SGL-41 &42:(CD) PH 5.6: Demonstrate Ability to educate public & Patient on various drugs uses	
	Thu	29-Feb-24	Com Med L-11 Case control study CM-7.5	Clinical Posting			Lunch	Path L-43 PA 10.2: Cysticercosis	Path SGL-43&44:(CD) PA-3.2 DOAP (Amyloidosis); Pharm SGL-43&44:(AB) PH 5.6: Demonstrate Ability to educate public & Patient on various drugs uses	
	Fri	1-Mar-24	O&G L-11 Use of USG in the initial assessment and monitoring in pregnancy; PC and PCPNDT Act OG 8.8 & OG 20.3	Clinical Posting			Lunch	FMT L-9 (FM 2.21): Mech Asphyxia-II Hanging	Micro SGL-39&40: (CD) Diagnostic method in infective endocarditis MI 2.3;FMT SGL-39&40: (AB) (FM5.1) For Psy-I: Intro+ Classification, PTSD	
	Sat	2-Mar-24	Pharm L-30 PH1.14(a)II Anti-Cholinergic drugs	PN-20, Module 2.4 Vaccination strategies & Implementation Visit to PHC (Group A to PHC-1) Com Med. Dept.	PN-21, Module 2.4 Vaccination strategies & Implementation Visit to PHC (Group B to PHC-2) Com Med. Dept.	Mentor-Mentee Interaction	Lunch	Path L-44 PA 7.1a:Neoplasia; benign neoplasm	Sports & Extra-Curricular Activities	
	SUNDAY									

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 12	Mon	4-Mar-24	Surg L-11 SU30.5: Hydrocele	Clinical Posting			Lunch	Micro L-22 Diarrhoea & Dysentery MI 3.1	Micro SGL-41&42:(AB) HIV:MI 2.7: FMT SGL-41&42:(CD) (5.2) For Psy-II: Hallucination, Illusion Delusion	
	Tue	5-Mar-24	Path L-45 PA – 16.1-16.3 Haemolytic anaemia	Clinical Posting			Lunch	Micro L-23 HIV MI 2.7	Path L-46 PA 7.1b: Neoplasia; malignant neoplasm	Pharm L-31 PH1.14(a)II Anti- Cholinergic drugs
	Wed	6-Mar-24	Med L- 12 HIV: (IM 6.1, 6.2, 6.5, 6.6) [VI-MI]	Clinical Posting			Lunch	Pharm L-32 PH1.16:Autacoids- V	Path SGL-45&46:(AB) PA 20.1 Plasma Cell myeloma; Pharm SGL-45&46:(CD) PH1.63 Drug regulation acts & other legal Expects	
	Thu	7-Mar-24	Com Med L-12 Cohort study CM-7.5	Clinical Posting			Lunch	Path L-47 PA 10.3: Leprosy [VI-MI] [HI-IM]	Path SGL-47&48:(CD) PA 20.1 Plasma Cell myeloma; Pharm SGL-47&48:(AB) PH1.63 Drug regulation acts & other legal Expects	
	Fri	8-Mar-24	O&G L-12 Classify, define & discuss the aetiology and management of abortions including threatened, incomplete, inevitable, missed & septic OG 9.1	Clinical Posting			Lunch	FMT L-10 (FM 2.21) Mech Asphyxia-III Strangulation	Micro SGL-43&44:(CD) HIV:MI 2.7: FMT SGL-3&44(AB) (5.2) For Psy-II: Hallucination, Illusion Delusion	
	Sat	9-Mar-24	Pharm L-33 PH 1.24 Diuretics	PN-22, Module 2.4 Vaccination strategies & Implementation Discussion and closure (Whole Batch) Com Med. & Biochem Depts.	PN-23, Module 2.5 Therapeutic strategies & New drug development Exploratory and interactive theory session (Whole Batch) Pharm. Dept.	PN-24: Module 2.5 Therapeutic strategies & New drug development Small Group discussion- New Drug Development (Whole Batch) Pharm. Dept.	Lunch	Path L-48 PA 10.4a: Common bacterial, viral, protozoal and helminthic diseases	Sports & Extra-Curricular Activities	
				SUNDAY						

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm	
Week 13	Mon	11-Mar-24	Surg L-12 SU29.1: Haematuria	Clinical Posting				Lunch	Micro L-24 Food Poisoning MI 3.5	Micro SGL-45&46(AB) Malaria Parasite MI 2.6 (DOAP);FMT SGL-45&46(CD) FM 5.5: Psy-VII: Delirium tremens	
	Tue	12-Mar-24	Path L-49 PA 3.1b: Amyloidosis	Clinical Posting				Lunch	Micro L-25 Viral Hepatitis MI 3.7	Path L-50 PA 10.4b: Common bacterial, viral, protozoal & helminthic diseases	Pharm SDL-4 Tutorial on Adrenergic & Antiadrenergic drugs
	Wed	13-Mar-24	Med L-13 HIV - Opportunistic Infections (IM 6.3, 6.4, 6.18) [VI-MI]	Clinical Posting				Lunch	Pharm L-34 PH 1.27: Anti- hypertensive Drugs - I	Path SGL-49&50: (AB) PA 19.6, 19.7-Gross & microscopy of enlarged spleen; Pharm SGL-49&50: (CD)PH3.7 List of Essential medicine	
	Thu	14-Mar-24	Com Med L-13 Association and causation CM 7.8	Clinical Posting				Lunch	Path L-51 PA 31.4: Breast – Gynaecomastia	Path SGL-51&52: (CD) PA 19.6, 19.7 Gross & microscopy of enlarged spleen; Pharm SGL-51&52 (AB): PH3.7 List of Essential medicine	
	Fri	15-Mar-24	O&G-L-13 Acute abdomen in early pregnancy ; Medical & Surgical Management. OG 9.3 B	Clinical Posting				Lunch	FMT L-11 (FM 2.22) Mech Asphyxia-IV Suffocation, Traumatic asphyxia, Sexual asphyxia	Micro SGL-47&48 (CD) Malaria Parasite MI 2.6 (DOAP);FMT SGL-47&48 (AB), FM 5.5: Psy-VII: Delirium tremens [SDL]	
	Sat	16-Mar-24	Pharm L-35 PH 1.27 Anti- Hypertensive Drugs– II	PN-25, Module 2.5 Therapeutic strategies & New drug development Small Group discussion Therapeutic Strategies (Whole Batch) Gen. Med. Dept	PN-26, Module 2.5 Therapeutic strategies & New drug development Visit/ Video of Stages of Drug Development (Whole Batch) Pharm. Dept.	PN-27, Module 2.5 Therapeutic strategies & New drug development Visit/ Video of Stages of Drug Development (Whole Batch) Gen. Med. Dept		Lunch	Path L-52: PA-12.1b Disorders caused by tobacco and alcohol	Sports & Extra-Curricular Activities	
SUNDAY											

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 14	Mon	18-Mar-24	Surg L-13 SU27.3: Vasospastic disorders	Clinical Posting			Lunch	Micro L-26 Anaerobic Infections MI 4.1	Micro SGL-49&50: [AB]; MI 3.4:Enteric fever (P) (DOAP); FMT SGL-49&50: [CD]:FM 5.3: For Psy: VIII Mental healthcare Act [SDL]	
	Tue	19-Mar-24	Path L-53 PA - 4.3, 4.4: Inflammation	Clinical Posting			Lunch	Micro L-27 Diarrhoea & Dysentery MI 3.1 [VI-CM]	Path L -54 PA 7.2a: Neoplasia – Molecular basis-1	Pharm SDL-5 Autacoids
	Wed	20-Mar-24	Med L-14 HIV Management (1M 6.16-6.18) [VI-CM]	Clinical Posting			Lunch	Pharm L-36 PH 1.16: Autacoids-VII	Path SGL-53&54(AB) PA 20.1 Plasma Cell myeloma; Pharm SGL-53&54 (CD) PH3.8 Communicate with Pt.for proper use of medication	
	Thu	21-Mar-24	Com Med L-14 Dynamic of disease transmission CM 7.2	Clinical Posting			Lunch	Path L -55 PA 7.2b: Neoplasia – Molecular basis-2	Path SGL-55&56(CD) PA 20.1 Plasma Cell myeloma; Pharm SGL-55&56 (AB) PH3.8 Communicate with Pt.for proper use of medication	
	Fri	22-Mar-24	O&G L-14 Ectopic pregnancy and its medical & surgical management OG 9.3 A	Clinical Posting			Lunch	FMT L-12 (FM 2.23): Mech. Asphyxia-V Drowning	Micro SGL-51&52: [AB]; MI 3.4:Enteric fever (P) (DOAP); FMT SGL-51&52: [CD]; FM5.3: For Psy: VIII Mental healthcare Act [SDL]	
	Sat	23-Mar-24	Pharm L-37 PH 1.27 Anti-Hypertensive Drugs– III	AETCOM -10; Module 2.4: Working in a health care team “Tag along” session in hospital- (Group A,B, C & D and sent to 4 departments for Interaction with Nurse/Technicians/ HCW) Microbiology Dept.	AETCOM -11; Module 2.4: Working in a health care team “Tag along” session in hospital Group A,B, C & D and sent to 4 departments for Interaction with Nurse/Technicians /HCW) Microbiology Dept.	Mentor-Mentee Interaction	Lunch	Path SDL-1 PA6.4:Hemodynamics Normal haemostasis	Sports & Extra-Curricular Activities	
				SUNDAY						



NOIDA INTERNATIONAL INSTITUTE OF MEDICAL SCIENCES, GREATER NOIDA

Phase II TT for Batch 2022 w.e.f 18 December 2023

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm		
Week 15	Holi: Mon, 25 Mar, 2024											
		Tue	26-Mar-24	Path L-56 PA 7.2c; Neoplasia Molecular basis-3			Clinical Posting	Lunch	Micro L-28 Enteric fever, MI 3.3 [VI-CM,IM]	Path L-57 PA 28.4: Kidney – CRF [VI-IM]	Pharm SDL-6 Autacoids	
		Wed	27-Mar-24	Med L-15 Malaria –I (1M 4.6, 4.22) [VI-CM]			Clinical Posting	Lunch	Pharm L-38 PH 1.24: Anti- Diuretics	Path SGL-57&58:(AB) PA 22.1: DOAP - (ABO bloodgroupig; Pharm SGL-57&58: (CD) PH3.2:Prescription audit (SGL)		
		Thu	28-Mar-24	Com Med L-15 Infectious disease epidemiology (selected definitions) CM 7.2			Clinical Posting	Lunch	Path SDL-2 PA28.16 Urothelial tumors	Path SGL-59&60:(AB) PA 22.1: DOAP - (ABO bloodgroupig; Pharm SGL-59&60: (CD) PH3.2:Prescription audit (SGL)		
		Good Friday: Fri, 29 Mar 2024										
		Sat	30-Mar-24	Pharm L-39 PH 1.16 Autacoids- IX	AETCOM -12; Module 2.4: Working in a health care team “Tag along” session in hospital Group A,B, C & D and sent to 4 departmentst for Interaction with Nurse/Technicia ns/HCW) Microbiology Dept.	AETCOM -13; Module 2.4: Working in a health care team “Tag along” session in hospital Group A,B, C & D and sent to 4 departmentst for Interaction with Nurse/Technicia ns/HCW) Microbiology Dept.	PN-28, Module 2.5 Therapeutic strategies & New drug development Discussion and closure (Whole Batch) Pharm. Dept.	Lunch	Path SDL-3 PA 9.1: Immunity – Principles and mechanism	Sports & Extra-Curricular Activities		
	SUNDAY											

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 16	Mon	1-Apr-24	Surg L-14 SU27.4 Gangrene & Principles of amputation	Clinical Posting			Lunch	Micro L-29 Skin & Soft tissue, MI 4.3	Micro SGL-53&54 [AB] HIV MI 2.7; FMT- SGL-53&54 [CD]: (FM2.5-2.7): Sudden death and THOTA	
	Tue	2-Apr-24	Path I-58 PA-12.1a: Enumerate and describe the pathogenesis of disorders caused by air pollution	Clinical Posting			Lunch	Micro L-30 Acid-Peptic disease, MI 3.6 [VI-IM] [HL-PA]	Path L-59 PA 22.1: Blood banking – Blood group systems	Pharm SDL-7 Anti-Hypertensive
	Wed	3-Apr-24	Med L-16 Malaria II (IM 4.15, 4.23, 4.26) [VI-CM]	Clinical Posting			Lunch	Pharm L-40 PH1.30: Anti Arrhythmic - I	Path SGL-61&62(AB): Total Leucocyte count, Platelet count; Pharm SGL-61&62 (CD): PH 5.2-5.4 Optimal Use of drugs	
	Thu	4-Apr-24	Com Med L-16 Disease prevention and control: CM 7.2	Clinical Posting			Lunch	Path L-60 PA -22.2: Blood banking – compatibility testing	Path SGL-63&64 (CD): Total Leucocyte count, Platelet count; Pharm SGL-63&64 (AB): PH 5.2-5.4 Optimal Use of drugs	
	Fri	5-Apr-24	O&G L-15 Gestational trophoblastic neoplasms- CF, Investigations & Its management: OG 9.4	Clinical Posting			Lunch	FMT SDL-3 FM2.5- 2.7: Sudden death and THOTA	Micro SGL-55&56:[CD] HIV MI 2.7; FMT- SGL-55&56 [AB]: (FM2.5-2.7): Sudden death and THOTA	
	Sat	6-Apr-24	Pharm L-41 PH 1.30: Anti Arrhythmic – II [VI-IM]	AETCOM -27; Module 2.7: Bioethics continued – Introduction of case (Whole Batch) Pathology Dept.	AETCOM -14; Module 2.4: Small Group Discussion Session (Group A, audience Group B) Microbiology Dept.	AETCOM -15; Module 2.4: Small Group Discussion Session (Group B, audience Group A) Microbiology Dept..	Lunch	Path L-61 PA 7.5a: Neoplasia - immunology and the immune response to cancer	Sports & Extra-Curricular Activities	
				SUNDAY						

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm	
Week 17	Mon	8-Apr-24	Surg L-15 SU21.1: Salivary glands Disorders	Clinical Posting			Lunch	Micro L-31 Encephalitis MI 5.2	Micro SGL-57&58 [AB]; HIV, MI 2.7: (DOAP); FMT- SGL-57&58 [CD]-FM 5.5: Psy-VII: Delirium tremens		
	Tue	9-Apr-24	Path L-62 PA 21.2b: Haemorrhagic disorders- Haemophilia [VI-IM]	Clinical Posting			Lunch	Micro L-32 Acid-Peptic disease, MI 3.6	Path L-63 PA.13.1, 13.3, 13.4 Introduction to haematology	Pharm L-42 PH 1.29 CHF -I	
	Wed	10-Apr-24	Med L-17 Dengue: IM 4.3,4.16 [VI-CM]	Clinical Posting			Lunch	Pharm L- 43 Sulphonamide Cotrimoxazole & Quinolones: PH 1.42	Path SGL-65&66 [AB]; PA 16.7 Cross matching SGD; Pharm SGL-65&66 (CD) PH 5.6: Demonstrate Ability to educate public & Patient on various drugs uses D		
			Eid al-Fitr: Thurs, 11 Apr 2024								
	Fri	12-Apr-24	O&G L-16 Maternal pelvis and types, OG 14.1	Clinical Posting			Lunch	FMT L-14 (5.2) For Psy-II: Hallucination, Illusion, Delusion	Microbiology- SGL-59&60[CD]; HIV, MI 2.7: (DOAP); FMT- SGL-59&60 [AB]-FM 5.5: Psy-VII: Delirium tremens		
	Sat	13-Apr-24	Pharm L-44 PH 1.27 Anti-Hypertensive Drugs – III [VI-IM]	AETCOM -28; Module 2.7: Bioethics continued – Self-Directed Learning: Role Play/ Skit/ Debate/ Seminar (by Group A, Audience: Group B) Pathology Dept.	AETCOM -29; Module 2.7: Bioethics continued –Self-Directed Learning: Role Play/ Skit/ Debate/ Seminar (by Group B, Audience: Group A) Pathology Dept.	AETCOM -16; Module 2.5: Bioethics continued – Case studies on patient autonomy and decision making Introduction and Group Formation (Whole Batch) Pharmacology Dept.	Lunch	Path SDL -4 PA-12.1b disorders caused by tobacco and alcohol	Sports & Extra-Curricular Activities		
			Dr.Ambedkar Jayanthi: Sun, 14 Apr 2024								

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 18	Mon	15-Apr-24	Surg L-16 SU22.1 Thyroid- Applied anatomy and physiology [VI-AN]	Clinical Posting			Lunch	Micro L-33 Viral Hepatitis MI 3.7	Micro SGL-61&62 [AB];MI 3.4: Enteric fever (P),(DOAP); FMT SGL-61&62 FMT SGL- 67&68 (CD)-FM 5.3: For Psy: VIII Mental healthcare Act	
	Tue	16-Apr-24	Path L-65 PA 21.4,21.5a: Haemorrhagic disorders- DIC, Vit K deficiency [VI-BI]	Clinical Posting			Lunch	Micro L-34 STD MI 7.2	Path L-66 PA 21.4,21.5b: Haemorrhagic disorders- DIC, Vit K deficiency	Pharm L-45 Beta-Lactam Antibiotics PH 1.42
	Wed	17-Apr-24	Med L-18 Chikungunya / Typhus :IM 4.3, 4.16	Clinical Posting			Lunch	Pharm L-46 PH 1.17: L. A	Path SGL-67&68 (CD):PA 16.7 Cross matching SGD; Pharm SGL- 67&68 (AB) PH 5.6: Demonstrate Ability to educate public & Patient on various drugs uses	
	Thu	18-Apr-24	Com Med L-17 Investigation of epidemic, CM 7.7	Clinical Posting			Lunch	Path L-67 PA. 2.2- 2.4: Cell Injury and Adaptation	Path SGL-69&70 [AB]; PA 22.1 (ABO blood grouping; Pharm SGL-69&70(CD) PH 5.6: Tutorial on Pharmacokinetics	
	Fri	19-Apr-24	O&G L-17 Normal labor, mechanism of labor in occipito-anterior presentation: OG 13.1 A	Clinical Posting			Lunch	FMT L-15 FM 5.2: For Psy-III: OCD, Lucid interval [L]	Micro SGL-63&64[CD];MI 3.4: Enteric fever (P),(DOAP); FMT SGL-63&64 (AB)-FM 5.3: For Psy: VIII Mental healthcare Act	
	Sat	20-Apr-24	Pharm L-47 Aminoglycoside Antibiotics PH 1.43	Com Med L-18 Introduction to epidemiology & descriptive epidemiology, CM 7.5	AETCOM -30; Module 2.7: Bioethics continued – Anchoring Lecture (Whole Batch) Pathology Dept.	AETCOM -17; Module 2.5: Bioethics continued – Case studies on patient autonomy and decision making Case introduction (Group A & B) Pharmacology Dept	Lunch	Path SDL-5 PA 7.5b: Neoplasia - immunology and the immune response to cancer	Sports & Extra-Curricular Activities	
				SUNDAY						

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 19			22-Apr-24; Mon: Terminal -I Examinations Microbiology							
			23-Apr-24; Tue: Terminal -I Examinations Pathology							
			24-Apr-24; Wed: Terminal -I Examinations Pharmacology							
			25-Apr-24; Thurs: Terminal -I Examinations FMT							
			26-Apr-24; Fri: Terminal -I Examinations Practical's-1							
			27-Apr-24; Sat: Terminal -I Examinations Practical's -2							
			SUNDAY							
Week 20			29-Apr-24; Mon: Terminal -I Examinations Practical's -3							
			30-Apr-24; Tue: Terminal -I Examinations Practical's-4							
	Wed	1-May-24	Med L-19 Japanese Encephalitis: IM 4.3, 4.12, 4.16 [VI-CM]	Clinical Posting			Lunch	Pharm L-48 PH 1.31: Hypolipidaemic drugs	Path SGL-71&72 [AB]; PA 22.1 (ABO blood grouping; Pharm SGL-71&72(CD) PH 5.6: Tutorial on Pharmacokinetics	
	Thu	2-May-24	Com Med L-19 Screening: CM 7.6	Clinical Posting			Lunch	Path L-68 PA 7.3a: Neoplasia - Carcinogenesis	Path SGL-73&74[AB];PA 16.5 Peripheral smear in different haemolytic anemias; Pharm SGL-73&74(CD) PH5.6: Tutorial on Pharmacodynamics	
	Fri	3-May-24	O&G L-18 Labour-Monitoring Including partogram; principles of induction & acceleration ; OG 13.1B [VI-PY]	Clinical Posting			Lunch	FMT L-16 (FM 2.21) Mech. Asphyxia-III Strangulation	Micro SGL-65&66 (AB)Viral Hepatitis (P) MI 3.8 (DOAP); FMT SGL-65&66[CD]-FM 3.2:Footprints, Scars, tattoo marks, superimposition, etc.	
	Sat	4-May-24	Pharm L-49 PH 1.38: Corticosteroids	AETCOM -31; Module 2.7: Bioethics continued Discussion & Closure (Whole Batch) Pathology Dept.	AETCOM -18 Module 2.5: Bioethics continued – Case studies on patient autonomy and decision making Self-Directed Learning: Role Play/ Skit/ Debate/ Seminar (by Group A, Audience: Group B) Pharmacology Dept	AETCOM -19 Module 2.5: Bioethics continued – Case studies on patient autonomy and decision making Self-Directed Learning: Role Play/ Skit/ Debate/ Seminar (by Group B, Audience: Group A) Pharmacology Dept.	Lunch	Path L-69 PA 7.3b Neoplasia Carcinogenesis	Sports & Extra-Curricular Activities	
			SUNDAY							

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 21	Mon	6-May-24	Surg L-17 SU22.2 Thyroidal swellings	Clinical Posting			Lunch	Micro L-35 Bone and Joint infection: MI 4.2	Micro SGL-67&68 (CD)Viral Hepatitis (P) MI 3.8; FMT SGL-67&68 [CD]-FM 3.2:Footprints, Scars, tattoo marks, superimposition, etc.	
	Tue	7-May-24	Path L-70 PA 7.3c: Neoplasia - Carcinogenesis	Clinical Posting			Lunch	Micro L-36 UTI: MI 7.3	Path L-71 PA 22.4: Blood banking – Blood components	Pharm SDL-8 PH 1.38: Corticosteroids
	Wed	8-May-24	Med L-20 Exanthematous Fever (4.3, 4.12, 4.16)-1	Clinical Posting			Lunch	Pharm L-50 PH1.36b: Parathyroid disorders & osteoporosis drugs	Path SGL-75&76[AB];PA 16.5 Peripheral smear in different haemolytic anemias; Pharm SGL-75&76(CD) PH 5.6:Tutorial on Pharmacodynamics	
	Thu	9-May-24	Com Med L-20 Class Test	Clinical Posting			Lunch	Path L-72 PA– 15.1, 15.2 & 15.4: Macrocytic anemia	Path SGL-77&78 [AB]PA 13.5, 14.3 Peripheral smear in microcytic anemia; Pharm SGL-77&78 [CD]: PH3.8 Communicate with Pt. for proper use of medication	
	Fri	10-May-24	O&G L-19 Placental delivery, management & active management of IIIrd stage: OG 13.1 C	Clinical Posting			Lunch	FMT SDL-4 (FM5.1) For Psy-I: Intro +Classification, PTSD	Micro SGL-69&70[AB]:HIV, HCV, HBSAg Viral Markers (P) MI 3.8 ;FMT SGL-69&70 [CD]-FM (5.3): For Psy-IV: Civil Responsibility	
	Sat	11-May-24	Pharm L-51 1.37:Anterior Pituitary Hormones[VI-AN,PY]	Com Med SDL-1 Small pox and chicken pox: CM 8.1	AETCOM -20 Module 2.5: Bioethics continued – Case studies on patient autonomy and decision making Anchoring Lecture (Whole Batch) Pharmacology Dept.	AETCOM -21 Module 2.5: Bioethics continued – Case studies on patient autonomy and decision making Case Resolution (Whole Batch) Pharmacology Dept.	Lunch	Path L-73 PA 22.6: Blood banking – Transfusion reactions	Sports & Extra-Curricular Activities	
				SUNDAY						

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm	
Week 22	Mon	13-May-24	Surg L-18 SU3.1 Use of blood and blood products and complications of blood transfusion	Clinical Posting			Lunch	Micro L-37 Meningitis MI 5.1	Micro SGL-71&72[CD):HIV,HCV,HBSAg Viral Markers (P) MI 3.8; FMT SGL-71&72[AB]-FM (5.3): For Psy-IV: Civil Responsibility		
	Tue	14-May-24	Path L-74 PA 7.4a: Neoplasia – Paraneoplastic syndromes	Clinical Posting			Lunch	Micro L-38 VRTI MI 6.1 -1	Path L-75 PA 7.4b: Neoplasia – Paraneoplastic syndromes	Pharm L-52 PH 1.39: Contraceptives	
	Wed	15-May-24	Med L-21 Exanthematous Fever (4.3,4.12,4.16)-2	Clinical Posting			Lunch	Pharm L-53 PH 1.36: Diabetes mellitus- I	Path SGL-79&80 [CD]PA 13.5, 14.3 Peripheral smear in microcytic anemia; Pharm SGL-79&80 [AB]: PH3.8 Communicate with Pt. for proper use of medication		
	Thu	16-May-24	Com Med SGT-1 Infectious disease epidemiology (selected definitions) CM 7.2	Clinical Posting			Lunch	Path L-76 PA 12.3: Obesity and its consequences	Path SGL-81&82 [AB] PA 15.3: Macrocytic anemia; Pharm SGL-81&82 [CD]: PH1.60(a) Pharmacogenomics		
	Fri	17-May-24	O&G L-20 Obstructed labor, CF, Prevention & Management OG 14.2	Clinical Posting			Lunch	FMT L-17 (FM 2.21) Mech. Asphyxia-II Hanging	Micro SGL-73&74[AB]) Bone and Joint infection MI 4.2 (DOAP); FMT- SGL-73&74 [CD]-FM (5.3): For Psy-IV: Civil Responsibility		
	Sat	18-May-24	Pharm L-54 PH1.36: Diabetes mellitus-II [VI,IM]	Com Med SDL-2 Measles and rubella: CM 8.1	Micro L-39 Basics of Infections control (SDL) MI 8.6 (L) + Phase -2 Pendemic module 2.1 Contact Precautions	AETCOM - 22; Module 2.6: Bioethics continued – Introduction of case (Whole Batch) Pharmacology Dept		Lunch	Path SDL-6 PA -22.2: Blood banking – compatibility testing	Sports & Extra-Curricular Activities	
				SUNDAY							

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 23	Mon	20-May-24	Surg L-19 SU14.3 Surgical wound closure & anastomosis (sutures, knots & needles)	Clinical Posting			Lunch	Micro L-40 VRTI MI 6.1 -2	Micro SGL-75&76 [CD] Bone and Joint infection MI 4.2 (DOAP);FMT- SGL-75&76[AB]-FM (5.3); For Psy-IV: Civil Responsibility	
	Tue	21-May-24	Path L-77 PA 24.2: GIT-Peptic ulcer disease [VI-IM]	Clinical Posting			Lunch	Micro L-41 Opportunistic Infection: MI 8.2	Path L-78 PA 28.14, Kidney- Renal Tumors	Pharm L-55 PH 1.34(1): Peptic ulcer - 1
	Wed	22-May-24	Med L-22 Cholera & Gastro Enteritis: (IM 16.1-16.10)	Clinical Posting			Lunch	Pharm L-56 PH 1.34(1) Peptic ulcer-2	Path SGL-83&84[CD] PA 15.3 Macrocytic anemia; Pharm SGL-83&84[AB]: PH1.60(a) Pharmacogenomics	
	Thu	23-May-24	Com Med SGT-2 Calculation for disinfecting water CM 3.2	Clinical Posting			Lunch	Path L-79 PA 24.2, 24.3: GIT-Peptic ulcer disease	Path SGL-85&86 [AB] PA 22.5: Blood banking –infections transmitted by transfusion; Pharm SGL-85&86[CD]: Tutorial on Adrenergic & Antiadrenergic drugs	
	Fri	24-May-24	O&G L-21 Lactation-Physiology importance and the technique of breast feeding :OG 17.1 & OG 17.2	Clinical Posting			Lunch	FMT SDL-5 (FM14.18) Prepare MLR in police/judicial custody; (FM14.22) Recording of evidence	Micro SGL-77&78 [AB]:Skin & Soft tissue (P) MI 4.3 (DOAP); FMT- SGL-77&78[CD]: (FM 2.15) NHRC Guidelines for autopsy case of in death in Custody	
	Sat	25-May-24	Pharm L-57 PH 1.47: Kala Azar, amebiasis & intestinal helminthiasis [VI-CM,IM]	Com Med SDL-3 Influenza CM8.1	AETCOM -23; Module 2.6: Bioethics continued –Self-Directed Learning: Role Play/ Skit/ Debate/ Seminar (by Group A, Audience: Group B) Pharmacology Dept.	AETCOM -24 Module 2.6: Bioethics continued – Self-Directed Learning: Role Play/ Skit/ Debate/ Seminar (by Group B, Audience: Group A) Pharmacology Dept.	Lunch	Path SDL-7 PA 7.4a: Neoplasia – Paraneoplastic syndromes	Sports & Extra-Curricular Activities	
				SUNDAY						

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm	
Week 24	Mon	27-May-24	Surg L-20 SU6.1 Surgical Infections [VI-MI]	Clinical Posting				Lunch	Micro L-42 Zoonotic diseases (P) MI 8.1 (DOAP)	Micro SGL-79&80 [CD]:Skin & Soft tissue (P) MI 4.3; FMT-SGL-79&80[AB]: (FM 2.15) NHRC Guidelines for autopsy case of in death in Custody	
	Tue	28-May-24	Path L-80 PA 24.4: GIT- Carcinoma of the stomach	Clinical Posting				Lunch	Micro L-43 STD: MI 7.2 [VI-IM,CM]	Path L-81 PA 26.1: Respiratory system- Pneumonia	Pharm L-58 PH 1.20:Alcohols
	Wed	29-May-24	Med L-23 Enteric fever & Brucellosis –II (IM 4.3, 4.16, 25.1)	Clinical Posting				Lunch	Pharm L-59 PH 1.34(3,4): Antidiarrhoeal & laxatives [VI-CM,IM]	Path SGL-87&88[CD] PA 22.5: Blood banking –infections transmitted by transfusion; Pharm SGL-87&88 [AB]: Tutorial on Adrenergic & Antiadrenergic drugs	
	Thu	30-May-24	Com Med SGT-3 Housing and disposal of human excreta CM 3.4,3.5	Clinical Posting				Lunch	Path L-82 PA 28.16: Kidney – Urothelial tumours- Revision	Path SGL-89&90[AB] PA 6.7: Gross and microscopic features of infarction; Pharm SGL-89&90 [CD]: Tutorial Autacoids	
	Fri	31-May-24	O&G L-22 Puerperium, its complications, diagnosis and management: OG 19.1	Clinical Posting				Lunch	FMT L-18 FM (2.9, 2.10) Putrefaction, Mummification, Maceration, Adipocere Time since death	Micro SGL-81&82 [AB] Encephalitis (P) MI 5.3; FMT SGL-81&82 [CD] (FM 2.17, 2.18) Crime scene investigation & Exhumation	
	Sat	1-Jun-24	Pharm L-60 PH 1.49: Anticancer- I [VI-IM]	AETCOM -32; Module 2.8: What does it mean to be family member of a sick patient? - Hospital visit & interviews (Group A-Medicine Ward, Group B-Surgery Ward,) Microbiology Dept.	AETCOM -33; Module 2.8: What does it mean to be family member of a sick patient? - Hospital visit & interviews (Group C- Paediatrics Ward, Group D- O & G Ward) Microbiology Dept.	AETCOM -25; Module 2.6: Bioethics continued – Anchoring Lecture (Whole Batch) Pharmacology Dept.		Lunch	Path SDL-8 PA 28.14, Kidney- Renal Tumors	Sports & Extra-Curricular Activities	
	SUNDAY										

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 25	Mon	3-Jun-24	Surg L-21 SU7.1: Surgical audit	Clinical Posting			Lunch	Micro L-44 Hand washing (DOAP) MI 8.7	Micro SGL-83&84 [CD] Encephalitis MI 5.3; FMT SGL-83&84 [AB] (FM 2.17, 2.18) Crime scene investigation & Exhumation	
	Tue	4-Jun-24	Path L-83 PA 26.2: Respiratory system-, Lung abscess	Clinical Posting			Lunch	Micro L-45 Zoonotic diseases MI 8.1	Path L-84 PA 24.6a: GIT- Inflammatory bowel disease-1	Pharm L-61 PH 1.49 Anticancer- II
	Wed	5-Jun-24	Med L-24 Tetanus; Diphtheria (IM 25.1-25.4, 25.7, 25.8)	Clinical Posting			Lunch	Pharm L-62 PH 1.51: Environmental pesticides, food adulterants (seminar)	Path SGL-91&92 [CD] PA 6.7: Gross and microscopic features of infarction; Pharm SGL- 91&92[AB]: Tutorial Autacoids-	
	Thu	6-Jun-24	Com Med SGT-4 Housing and disposal of human excreta CM 3.4,3.5	Clinical Posting			Lunch	Path L-85 PA 24.6 b: GIT- Inflammatory bowel disease-2	Path SGL-93&94[AB] PA 23.3: Liver function tests (Revision); Pharm SGL-93&94 [CD]: Cholinergic & Anti-Cholinergic drugs	
	Fri	7-Jun-24	O&G L-23 Contraceptive Methods - types, indications, technique & complications; failure rate including ECP: OG 21.1	Clinical Posting			Lunch	FMT L-19 FM 1.5, 1.6: Legal procedures- III, Court procedures & Witness, perjury	Micro SGL-85&86 [AB]:VRTI MI 6.2 (DOAP); FMT SGL- 85&86[CD]FM (5.3): For Psy- IV: Civil Responsibility	
	Sat	8-Jun-24	Pharm L-63 PH 1.51: Environmental pesticides, food adulterants (seminar)	Com Med SDL- 4 Medical entomology CM 3.7	AETCOM -34; Module 2.8: What does it mean to be family member of a sick patient? - Large Group Discussions with patients' relatives (Group A-Medicine Ward, Group B- Surgery Ward, Group C-Paediatrics Ward, Group D- O & G Ward) Microbiology Dept.	AETCOM -26; Module 2.6: Bioethics continued – Discussion and Closure (Whole Batch) Pharmacology Dept.	Lunch	Path L-86 PA 35.1: CNS- Meningitis [VI-IM]	Sports & Extra-Curricular Activities	
	SUNDAY									
Wk 26	10 to 16 June 2024; Mon to Sun: Summer Vacation									

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 27			Eid al-Adha: Mon, 17 Jun 2024							
	Tue	18-Jun-24	Path L-87 PA 24.7 :GIT- carcinoma of the colon	Clinical Posting			Lunch	Micro L-46 Genitourinary MI 7.1	Path L-88 PA26.3a:Respi ratory system – COPD	Pharm SDL-9 PH 1.36: Diabetes mellitus
	Wed	19-Jun-24	Med L-25 Enteric fever & Brucellosis – I (IM 4.3, 4.16, 25.1)	Clinical Posting			Lunch	Pharm L-64 PH 1.57: Drugs for skin disorder-1	Path SGL-95&96[CD] PA 23.3: Liver function tests (Revision);Pharm SGL- 95&96[AB]:Cholinergic & Anti- Cholinergic drugs	
	Thu	20-Jun-24	Com Med SGT-5 Housing and health CM 3.5	Clinical Posting			Lunch	Path L-89 PA26.3b: Respiratory system – COPD	Path SGL-97&98 [AB] PA 22.7 Blood banking –Principles and procedure of autologous transfusion; Pharm SGL-97&98 [CD]:PH 1.51: Environmental pesticides, food adulterants (seminar)	
	Fri	21-Jun-24	O&G L-24 Puerperal sterilization, Permanent methods of contraception, PPIUCD programme OG 19.1,21.1, 21.2	Clinical Posting			Lunch	FMT L-20 (FM 1.3) Legal procedures- 1 IPC, CrPC, IEA, Inquest, Offences	Micro SGL-87&88 [CD] VRTI MI 6.2 (DOAP); Pharm SGL- 99&100 [AB] PH3.2:Prescription audit	
	Sat	22-Jun-24	Pharm L-65 PH 1.57: Drugs for skin disorder-2 [VI-IM]	Com Med SGT- 6 Medical Entomology CM 3.7	AETCOM -35; Module 2.8: What does it mean to be family member of a sick patient? - Self-Directed Learning: Role Play/ Skit/ Debate/ Seminar (by Group A, Audience: Group B) Microbiology Dept.	AETCOM -36; Module 2.8: What does it mean to be family member of a sick patient? -Self- Directed Learning: Role Play/ Skit/ Debate/ Seminar (by Group B, Audience: Group A) Microbiology Dept.	Lunch	Path SDL-9 PA 26.2: Respiratory system- Lung abscess	Sports & Extra-Curricular Activities	
				SUNDAY						

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm	
Week 28	Mon	24-Jun-24	Surg L-22 SU14.1: Aseptic techniques, sterilization and disinfection	Clinical Posting				Lunch	Micro L-47 Food, Air, Water Bacteria MI 8.8	Micro SGL- 89&90 [AB] Zoonotic diseases (P) MI 8.1 (DOAP); Path SGL-99&100 [CD] Fibro adenoma Breast-Revision	
	Tue	25-Jun-24	Path L-90 PA 24.5 GIT- TB Intestine [VI-IM]	Clinical Posting				Lunch	Micro L-48 Emerging infections MI 8.4 [VICM,IM]	Path L-91 PA 26.5a: Respiratory system – Occupational lung diseases	Pharm SDL-10 PH1.36b I Parathyroid disorders & osteoporosis drugs
	Wed	26-Jun-24	Med L-26 Rabies(IM 25.1-25.4,25.7, 25.8)	Clinical Posting				Lunch	Pharm L-66 PH 1.58: Drug (Ocular disorder)	Path SGL-101 &102 [CD] PA 22.7 Blood banking –Principles and procedure of autologous transfusion; Pharm SGL-101&102 [AB]; PH 1.51: Environmental pesticides, food adulterants (seminar)	
	Thu	27-Jun-24	Com Med SGT-7 National Population policy CM-9.6	Clinical Posting				Lunch	Path L-92 PA 26.5b: Respiratory system – Occupational lung diseases	Path SGL-103&104 [AB] PA 16.6 Peripheral smear in haemolytic anemia; Pharm SGL-103&104[CD]:Tutorial on Pharmacodynamics	
	Fri	28-Jun-24	O&G L-25 MTP-Legal aspects, indications, complications & management: OG 20.1	Clinical Posting				Lunch	FMT L-21 (1.1,1.2) Introduction & History of FM-Revision	Micro SGL-91&92[CD] Zoonotic diseases (P) MI 8.1 (DOAP); Pharm SGL-105&106 [AB] PH3.2:Prescription audit	
	Sat	29-Jun-24	Pharm L-67 PH 1.41: Drugs acting on Uterus [VI-OG]	Com Med SDL-5 CM 3.5: Housing & Health	Pharm L-68 PH 1.40 Infertility [VI-OG]	AETCOM -37; Module 2.8: What does it mean to be family member of a sick patient? - Discussion and closure (Whole Batch) Microbiology Dept.		Lunch	Path L-93 PA 26.4: Respiratory system- Pulmonary tuberculosis	Sports & Extra-Curricular Activities	
SUNDAY											

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm	
Week 29	Mon	1-Jul-24	Surg L-23 SU15.1: Hospital waste Management & appropriate methods of disposal	Clinical Posting				Lunch	Micro L-49 Choosing diagnostic Methods MI 8.13	Micro SGL-93&94[AB] UTI (L) MI 7.3 -Revision ; Path SGL-105&106 [CD] Fibroadenoma Breast- Revision	
	Tue	2-Jul-24	Path L-94 PA 35.3: CNS- Meningitis	Clinical Posting				Lunch	Micro L-50 Food, Air, Water Bacteria MI 8.8	Path L-95 PA 27.1a: CVS- Arteriosclerosis and Atherosclerosis	Pharm SDL-11 PH 1.13(a) Adrenergic drugs
	Wed	3-Jul-24	Med L-27 Pneumonia IM 3.1-3.7)	Clinical Posting				Lunch	Pharm L-69 PH 1.44: Anti tubercular drugs-I [VI-CM,IM]	Path SGL-107&108 [CD] PA 16.6 Peripheral smear in Hemolytic anemia; Pharm SGL-107&108 [AB]:Tutorial on Pharmacodynamics	
	Thu	4-Jul-24	Com Med SGT-8 Vaccination Strategies including development & implementation	Clinical Posting				Lunch	Path L-96 PA 27.1b: CVS- Arteriosclerosis and Atherosclerosis [VI-IM]	Path SGL-109&110 [AB] PA-25.5: Portal hypertension, CVC, Liver (Hepatobiliary system); Pharm SGL-109&110[CD]:PH 3.3 Evaluation of drug Promotional Literature	
	Fri	5-Jul-24	O&G L-26 Sexually transmitted infections OG 27.1 [VI-CM,PH] [HI-IM]	Clinical Posting				Lunch	Pharm L-70 PH 1.44: Anti tubercular drugs-II	Micro SGL-95&96 [CD] UTI (L) MI 7.3 -Revision; Pharm SGL-111&112 [AB] Cholinergic & Anti-Cholinergic drugs-Revision	
	Sat	6-Jul-24	Pharm L-71 PH 1.19 (20,21,22,23,24,25,26) Anti-depressant -I	Com Med SDL-6 Disposal of human excreta and sewage CM 3.4	Micro L-51 IOR MI 8.15	Pharm L-72 PH 1.20: Alcohols		Lunch	Path L-97 PA 26.6 Respiratory system- Tumours of Lung	Sports & Extra-Curricular Activities	
				SUNDAY							

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 30	Mon	8-Jul-24	Surg L-24 SU9.1 Surgical Patients: Choose investigations and interpret the investigative data	Clinical Posting			Lunch	Micro L-52 National Health Program MI 8.16	Micro SGL-97&98[AB] LRTI Gram/ ZN staining MI 6.3 ; Path SGL-111 &112 [CD] PA-31.2,31.3 Carcinoma Breast	
	Tue	9-Jul-24	Path L-98 PA 35.2 CNS-tumours [VI-IM]	Clinical Posting			Lunch	Micro L-53 Identification of Bacteria MI 8.10	Path L-99 PA 27.8 Acute coronary syndromes	Pharm SDL-12 PH 5.2 Optimal Use of drugs
	Wed	10-Jul-24	Med L-28 Pneumonia Clinical Features & Investigation (IM 3.15-3.19)	Clinical Posting			Lunch	Pharm L-73 PH 1.34(1) Peptic ulcer	Path-SGL 113&114 :[CD] PA 25.5: Portal hypertension, CVC, Liver (Hepatobiliary system); Pharm-SGL 113&114 [AB]:PH 3.3 Evaluation of drug Promotional Literature (SDL)	
	Thu	11-Jul-24	Com Med SGT-9 Concept of health, dimensions and determinants CM 1.2	Clinical Posting			Lunch	Path L-100 PA 33.1: Chronic Osteomyelitis	Path-SGL-115&116[AB]PA 19.3, 19.5 (Gross and microscopic features of Tuberculosis lymphadenitis and Hodgkins lymphoma; Pharm-SGL-115&116[CD] PH 5.4 Patient Compliance	
	Fri	12-Jul-24	O&G L-26 HPV Infection OG 27.1	Clinical Posting			Lunch	Pharm L-74 PH 1.19(33,34,35,36) Opioids- I	Micro SGL-99&100 [CD] LRTI (P) Gram/ ZN staining MI 6.3 ; Pharm SGL-117&118 [AB] Cholinergic & Anti-Cholinergic drugs-Revision	
	Sat	13-Jul-24	Pharm L-75 PH 1.19 (1,2,3,4) Anxiolytics	Com Med SDL-7 Medical entomology CM3.7	Micro L-54 Anemia MI 2.4	Pharm L-76 PH 1.8 Drug interactions	Lunch	Path L-101 PA 27.2 CVS-Aneurysms	Sports & Extra-Curricular Activities	
				SUNDAY						

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 31	Mon	15-Jul-24	Surg L-25 SU29.1: Haematuria [HI-IM]	Clinical Posting			Lunch	Micro L-55 Zoonotic diseases MI 8.1	Micro SGL-101&102 [CD] LRTI (P) Gram/ ZN staining MI 6.3; Path SGL-117&118 [AB] PA- 31.2,31.3 Carcinoma Breast	
	Tue	16-Jul-24	Path L-102 PA 27.3 CVS- Aneurysms and heart Failure [VI-IM]					Clinical Posting		
	Wed	17-Jul-24	Med L-29 Pneumonia Management (IM 3.15-3.19)	Clinical Posting			Lunch			
	Thu	18-Jul-24	Com Med SGT-10 Epidemiological triad and natural history of disease CM1.3,1.4					Clinical Posting		
	Fri	19-Jul-24	O&G L-27 Test	Clinical Posting			Lunch			
	Sat	20-Jul-24	Pharm L-80 Environmental pesticides, food adulterants (seminar)-3					Com Med SDL-8 Fertility CM 9.2	Micro L-57 Immunological Mechanism MI 1.7	Pharm L-81 Environmenta l pesticides, food adulterants (seminar)-4
	SUNDAY									

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 32	Mon	22-Jul-24	Surg L-26 Test	Clinical Posting			Lunch	Micro L-58 Interpretation of Results (Case Discussions) MI 8.15	Micro SGL-105&106[AB] Sample Collection MI 8.11; Path SGL-123&124 [CD] PA 30.3 Leiomyoma & leiomyosarcoma- FGT-Revision	
	Tue	23-Jul-24	Path L-105 PA 23.3: Cardiac function tests [VI-IM]	Clinical Posting			Lunch	Micro L-59 Diarrhea & Dysentery MI 3.2 - Revision	Path L-106 PA 27.4 CVS- Rheumatic Heart Disease	Pharm L-82 PH 1.19 (46- 49) Alzheimer's disease
	Wed	24-Jul-24	Med L-30 Tuberculosis –I IM 4.1-4.3, 4.12-4.14, 4.19, 4.20	Clinical Posting			Lunch	Pharm L-83 PH 1.27 Anti- Hypertensive Drugs–Revision	Path SGL-125&126[CD] PA28.2, 28.3 (AB) Pathological findings & presentation of ARF & CRF; Pharm-SGL-125&126 [AB]:Tutorial on Adrenergic & Antiadrenergic drugs	
	Thu	25-Jul-24	Com Med SGT-11 Insecticides and rodenticides CM3.8	Clinical Posting			Lunch	Path L-107 PA28.16 Urothelial tumors-Revision	Path SGL-127&128 [AB] PA 23.1 a Urine Examination DOAP; Pharm SGL-127&128 [CD] PH 5.1 Ethics on drug use	
	Fri	26-Jul-24	O&G L-28 HIV OG 27.3	Clinical Posting			Lunch	Pharm L-84 PH 5.1 Ethics on drug use-Revision	Micro SGL-107&108 [CD] Sample Collection MI 8.11; Pharm SGL129&130 [AB] PH 5.1 Ethics on drug use	
	Sat	27-Jul-24	Pharm L-85 PH1.5 Pharmacodynamics-1, Revision	Com Med SDL-9 National Population policy CM-9.6	Micro SDL-1 Sterilization & Disinfection MI 1.4	Pharm L-86 PH1.5 Pharmacodyn amics-2, Revision	Lunch	Path SDL-11 PA28.16 Urothelial tumors-Revision	Sports & Extra-Curricular Activities	
				SUNDAY						

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 33	Mon	29-Jul-24	Pharm L-87 PH(1.4) Pharmacokinetics-1, Revision	Clinical Posting			Lunch	Micro L-60 Skin & Soft tissue MI 4.3	Micro SGL-109&110 [AB] Lab Practices MI 8.14; Path SGL- 129&130[CD] PA 30.3 Leiomyoma & leiomyosarcoma- FGT-Revision	
	Tue	30-Jul-24	Path L-108 PA 30.1, 30.6 FGT- Chronic cervicitis Carcinoma cervix	Clinical Posting			Lunch	Micro SDL-3 Meningitis MI 5.1	Path L-109 PA 27.6a: CVS- Endocarditis	Pharm L-88 PH(1.4) : Pharmacokin etics-2, Revision
	Wed	31-Jul-24	Med L-31 Tuberculosis- II (IM 4.1-4.3, 4.12-4.14, 4.19, 4.20)	Clinical Posting			Lunch	Pharm L-89 PH 1.7 ADR	Path SGL-131 &132[CD] PA 23.1 a Urine Examination DOAP; Pharm SGL-131&132 [AB] PH 5.1 (SDL) Ethics on drug use	
	Thu	1-Aug-24	Com Med SGT-12 Demography & world population trends CM-9.1	Clinical Posting			Lunch	Path L-110 PA 27.6b: CVS- Endocarditis	Path SGL-133&134[AB];PA 23.3 Renal Function tests ; Pharm SGL-133&134[CD] PH 1.26 R.A.S	
	Fri	2-Aug-24	O&G L-29 Pelvic Inflammatory Disease OG 27.4	Clinical Posting			Lunch	Pharm L-90 PH 1.13(a)I Adrenergic drugs- Revision	Micro SGL-111&112 [CD] Lab Practices MI 8.14; Pharm SGL-135&136 [AB] PH 5.1 Ethics on drug use	
	Sat	3-Aug-24	Pharm L-91 CVS-Revision	Com Med SDL-10 Vaccination Schedule [VI-MI]	Micro L-61 Skin & Soft tissue MI 4.3	Pharm L-92 PH 1.13(a)V Adrenergic drugs- Revision	Lunch	Path L-111 PA 33.1: Chronic Osteomyelitis	Sports & Extra-Curricular Activities	
				SUNDAY						

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm	
Week 34	Mon	5-Aug-24	Pharm L-93 PH1.14(a)I: Cholinergic drugs- Revision	Clinical Posting				Lunch	Micro L-62 HIV-Revision	Micro SGL-113&114 [CD] Interpretation of Results (Case Discussions) MI 8.15; Path SGL-135&136 (AB) PA28.16 (AB) Urothelial tumors	
	Tue	6-Aug-24	Path L-112 PA 30.2, 30.7 FGT – Diseases of endometrium	Clinical Posting				Lunch	Micro L-63 Infection Control PPE MI 8.7 [VI-SU]	Path L-113 PA 27.5 a: CVS-Ischemic Heart disease	Pharm L-94 PH1.16: Autacoids- I Histamine & antihistamine
	Wed	7-Aug-24	Med L-32 Test	Clinical Posting				Lunch	Pharm L-95 Drugs affecting coagulation	Path SGL-137&138 [CD]; PA 23.3 Renal Function tests; Pharm SGL-137&138 [AB] PH 1.26 R.A.S	
	Thu	8-Aug-24	Com Med SGT-13 Population trends in India CM-9.3,9.4	Clinical Posting				Lunch	Path L-114 PA 33.1 Chronic Osteomyelitis	Path SGL-139&140 [AB]; PA 23.1b Urine Examination; Pharm SGL-139&140 [CD] PH 1.19(6,7,8,9,10)-Sedatives & Hypnotics	
	Fri	9-Aug-24	O&G L-30 Menopause & its management and the role of HRT OG 32.1	Clinical Posting				Lunch	Pharm L-96 PH 1.54 Vaccines uses SDL	Micro SGL-115&116 [AB] Interpretation of Results (Case Discussions) MI 8.15; Pharm SGL-141&142 [CD] PH 5.1 Ethics on drug use	
	Sat	10-Aug-24	Pharm L-97 PH 1.28 I H D - I	Com Med SGT- 14 Disease prevention and control: CM 7.2	Micro SDL-2 Infective Endocarditis MI 2.2	Pharm L-98 PH 1.36: Diabetes mellitus- I		Lunch	Path L-115 PA 30.4, FGT- Ovarian Tumours, Gestational trophoblastic neoplasms	Sports & Extra-Curricular Activities	
				SUNDAY							

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 35			12-Aug-24; Mon: Terminal -II Examinations Microbiology							
			13-Aug-24; Tue: Terminal -II Examinations Pathology							
			14-Aug-24; Wed: Terminal -II Examinations Pharmacology							
			Independence Day: Thurs,15 Aug 2024							
			16-Aug-24; Fri : Terminal -II Examinations Practical's-1							
			17-Aug-24; Sat :Terminal -II Examinations Practical's -2							
			SUNDAY							
Week 36			19-Aug-24; Mon : Terminal -II Examinations Practical's -3							
			20-Aug-24; Tue : Terminal -II Examinations Practical's-4							
	Wed	21-Aug-24	Micro SDL-4 National Health Program MI 8.16	Clinical Posting			Lunch	Pharm L-99 Principles of Pharmacology PH1.1(a)	Path SGL- 141&142[CD] PA 23.1b Urine Examination; Pharm SGL-143&144 [AB] PH 1.19 (6,7,8,9,10)-Sedatives & Hypnotics	
	Thu	22-Aug-24	Com Med SGT-15 Case control study CM-7.5	Clinical Posting			Lunch	Path L-116 PA— 30.3 (Leiomyoma & Leiomyosarcoma) (Female Genital Tract)	Path SGL- 143&144 [AB] PA 23.1c Urine Examination; Pharm SGL-145&146 [CD] PH 5.3 Motivate Patients with chronic disease	
	Fri	23-Aug-24	O&G L-31 Cervical cancer. Endometrial cancer, Ovarian cancer: OG 33.1A ,34.1A , 34.2A	Clinical Posting			Lunch	Pharm L-100 PH 1.19 (13,14,15,16,17)Anti -psychotic	Micro SGL-117&118 [CD] Encephalitis (P) MI 5.3; Pharm SGL-147&148 [AB] Pharm SGL-107&108[CD] PH 5.1 Ethics on drug use	
	Sat	24-Aug-24	Pharm L-101 PH 1.19 (27,28,29,30,31,32) Anti-manics -I	Com Med SGT-16 Concept of health, CM 1.2	Micro SDL-5 Sterilization & Disinfection MI 1.5	Pharm L-102 PH1.19 (37,38,39) Opioids- II	Lunch	Path L-117 PA 33.4: Rheumatoid arthritis	Sports & Extra-Curricular Activities	
			SUNDAY							

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 37	Mon	26-Aug-24	Pharm L-103 PH 1.19 (46- 49) Alzheimer's disease	Clinical Posting			Lunch	Micro L-64 Immune Response (MI 1.8)	Micro SGL-119&120 [AB] Encephalitis (P) MI 5.3; Path SGL-145&146 (CD) PA28.16 Urothelial tumors	
	Tue	27-Aug-24	Path L-118 PA 30.5:FGT- Ovarian Tumours, Gestational trophoblastic neoplasms	Clinical Posting			Lunch	Micro L-65 Immunological Mechanism MI 1.7	Path L-119 PA 27.7 CVS- Pericarditis	Pharm L-104 PH 1.19 (40,41,42,43,4 4,) Parkinsonism
	Wed	28-Aug-24	Micro L-66 Antigen Antibody Reaction MI1.10	Clinical Posting			Lunch	Pharm L-105 PH 1.19 (6,7,8,9,10) Sedatives & hypnotics	Path SGL-147&148 [CD] PA 23.1c Urine Examination; Pharm SGL-149&150 [AB] PH 5.3 Motivate Patients with chronic disease	
	Thu	29-Aug-24	Com Med SGT-17 Dimensions and determinants CM 1.2	Clinical Posting			Lunch	Path L-120 PA 27.9: CVS- Cardiomyopathies [VI-IM]	Path SGL-149&150 [AB] Introduction to Pathology Rotation + Microscopy PA.1.1; Pharm SGL-151&152[CD] PH1.11 Routes of drug administration	
	Fri	30-Aug-24	Path L-121 PA 27.10 CVS- Congenital heart diseases [VI-IM]	Clinical Posting			Lunch	Pharm L-106 PH1.1(a) Principles of pharmacotherapeuti cs -Revision	Micro SGL-121&122 [AB] Culture Media MI 8.10; Pharm SGL-153&154[CD] PH 1.19(33,34,35,36) Opioids- I	
	Sat	31-Aug-24	Pharm L-107 Principles of Pharmacology PH1.1(a)	Com Med SGT- 18 Epidemiological triad with examples CM1.3,1.4	Micro SDL-6 Drug Resistance & Antibiotic MI 1.6	Pharm L-108 PH1.1(b) Principles of pharmacother apeutics - Revision	Lunch	Path L-122 PA 33.2: Osteo sarcoma, Osteoclastoma	Sports & Extra-Curricular Activities	
				SUNDAY						

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm	
Week 38	Mon	2-Sep-24	Pharm L-109 PH 1.13(a)I: Adrenergic drugs	Clinical Posting				Lunch	Micro L-67 Immunodeficiency disease MI 1.10	Micro SGL-123&124 [CD] Culture Media; MI 8.10; Path SGL-151&152 (AB) PA 29.1 Testicular tumours	
	Tue	3-Sep-24	Path L-123 PA 33.3: Soft Tissue Tumours-Revision	Clinical Posting				Lunch	Micro L-68 Autoimmunity MI 1.10: Transplant & Cancer Immunology MI 1.11	Path L-124 PA 31.2: Breast – Carcinoma Breast	Pharm L-110 PH 1.8 Drug interactions
	Wed	4-Sep-24	Micro L-69 Hypersensitivity MI 1.10	Clinical Posting				Lunch	Pharm L-111 PH 1.53 Chelating agent	Path SGL-1153&154 [CD]Introduction to Pathology Rotation + Microscopy PA.1.1; Pharm SGL-155&156 [AB] PH1.11 Routes of drug administration	
	Thu	5-Sep-24	Com Med SGT-19 Natural history of disease CM1.3,1.4	Clinical Posting				Lunch	Path L-125 PA 33.2: Osteosarcoma, Osteoclastoma	Path SGL-155&156 [AB] PA – 31.3 Gross and microscopic features of Carcinoma Breast; Pharm SGL-157&158 [CD] PH1.64(a) I Drug development including phase of clin. Trials HI Pandemic Module 2.5	
	Fri	6-Sep-24	Path L-126 PA 33.2a: Bone tumours	Clinical Posting				Lunch	Pharm L-112 PH1.8 drug interactions	Micro SGL-125&126 [AB] Viral Hepatitis; MI 3.8; Pharm SGL-159&160[CD] PH 1.19(33,34,35,36) Opioids- I	
	Sat	7-Sep-24	Pharm L-113 PH(1.4)(I) Pharmacokinetics	Com Med SGT-20 Disposal of human excreta CM 3.4	Micro SDL-7 Anemia MI 2.4	Pharm L-114 PH(1.4)(II) Pharmacokine tics		Lunch	Path L-127 PA 33.2b: Bone tumours	Sports & Extra-Curricular Activities	
				SUNDAY							

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm	
Week 39	Mon	9-Sep-24	Pharm L-115 PH(1.4)(III) Pharmacokinetics	Clinical Posting				Lunch	Micro L-70 Filariasis: MI 2.5	Micro SGL-127&128 [CD] Viral Hepatitis; MI 3.8; Path SGL-157&158 (AB) PA 13.5, 18.1 Peripheral Blood smears & DLC	
	Tue	10-Sep-24	Path L-128 PA 31.1: Breast – Benign breast disease	Clinical Posting				Lunch	Micro L-71 Rheumatic fever & Diagnosis MI 2.1	Path L-129 PA 31.4: Breast- Gynaecomastia	Pharm L-116 PH(1.4)(IV) Pharmacokinetics
	Wed	11-Sep-24	Micro L-72 Infective endocarditis MI 2.2	Clinical Posting				Lunch	Pharm L-117 Beta-Lactam Antibiotics PH 1.42	Path SGL-159&160[CD] PA – 31.3 Gross and microscopic features of Carcinoma Breast; Pharm SGL-161&162[AB] PH1.64(a) I Drug development including phase of clin. trials(L) HI Pandemic Module 2.5	
	Thu	12-Sep-24	Com Med SGT-21 Sewage Disposal CM 3.4	Clinical Posting				Lunch	Path L-130 PA 25.3a: Hepatobiliary system – Viral Hepatitis	Path SGL-161&162 [AB] PA.13.5 Hb/ RBC & Increase / decrease causes; Pharm SGL- 163&164 [CD] PH 5.3 Motivate Patients with chronic disece; PH 5.4 Patient Compliance	
	Fri	13-Sep-24	Path L-131 PA 25.3b: Hepatobiliary system – Viral Hepatitis	Clinical Posting				Lunch	Pharm L-118 Sulphonamide Cotrimoxazole & Quinolones PH 1.42	Micro SGL-129&130 [CD] UTI MI 7.1; Pharm SGL-165&166 [AB] PH 1.19 (13,14,15,16,17) Anti-psychotic	
	Sat	14-Sep-24	Pharm L-119 Aminoglycoside Antibiotics PH 1.43-Revision	Com Med SGT- 22 CM 3.5: Housing & Health	Micro SDL-8 HIV MI 2.7 (L)	Pharm L-120 PH 1.34(1) Peptic ulcer		Lunch	Path L-132 PA 25.4a: Hepatobiliary system –Alcoholic liver disease,	Sports & Extra-Curricular Activities	
				SUNDAY							

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 40	Mon	16-Sep-24	Pharm L-121 PH 1.47 Kala-Azar, Ameobiasis & intestinal helminthiasis [VI-CM,IM]	Clinical Posting			Lunch	Micro L-73 Kala-azar: MI 2.5	Micro SGL-131&132[AB] UTI MI 7.1; Path SGL-163&164 (CD) PA 13.5, 18.1 Peripheral Blood smears & DLC	
	Tue	17-Sep-24	Path L-133 PA 25.4b: Hepatobiliary system -Cirrhosis [VI-IM]	Clinical Posting			Lunch	Micro L-74 Food Poisoning MI 3.5	Path L-134 PA 25.5: Hepatobiliary system -Portal Hypertension	Pharm L-122 PH 1.34(3,4) Antidiarhoeal & laxatives
	Wed	18-Sep-24	Micro L-75 Viral Hepatitis MI 3.7 [VI-IM]	Clinical Posting			Lunch	Pharm L-123 PH 1.40 Infertility	Path SGL-165&166 (CD)PA.13.5 Hb/ RBC & Increase / decrease causes; Pharm SGL-167&168 [AB] PH 5.3 Motivate Patients with chronic disease; PH 5.4 Patient Compliance	
	Thu	19-Sep-24	Com Med SGT-23 CM 3.5: Social Classification for Family Survey	Clinical Posting			Lunch	Path L-135 PA 25.6a: Hepatobiliary system - gall bladder diseases	Path SGL-167&168[AB] PA 34.4a Microscopy of skin Tumours; Pharm SGL- 169&170[CD] Drugs affecting Bleeding and Thrombosis-II	
	Fri	20-Sep-24	Path L-136 PA 25.6b: Hepatobiliary system - gall bladder diseases	Clinical Posting			Lunch	Pharm L-124 PH 1.31 Hypolipidaemic drugs	Micro SGL-133&134[AB] Lab Practices MI 8.14; Pharm SGL- 171&172 [CD] PH 1.19 (13,14,15,16,17) Anti-psychotic	
	Sat	21-Sep-24	Pharm L-125 Drugs affecting coagulation,	Path L-137 PA23.3: Liver function tests	Micro SDL-9 Anaerobic Infections MI 4.1	Pharm L-126 PH 1.27 Anti Hyper Tensive Drugs - I	Lunch	Path L-138 PA23.3: Thyroid function tests	Sports & Extra-Curricular Activities	
				SUNDAY						

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 41	Mon	23-Sep-24	Pharm L-127 PH 1.27 Anti-Hypertensive Drugs – II [VI-IM]	Clinical Posting			Lunch	Micro L-76 Diarrhoea & Dysentery MI 3.1	Micro SGL-135&136 [CD] Lab Practices MI 8.14; Path SGL-169&170 [AB] PA2.3,2.5 Intracellular accumulations and pigments Revision	
	Tue	24-Sep-24	Path L-139 PA7.4: Paraneoplastic syndrome- Revision	Clinical Posting			Lunch	Micro L-77 Acid-Peptic disease, MI 3.6	Path L-140 PA 28.1 Normal histology of Kidney	Pharm L-128 PH 1.27 Anti-Hypertensive Drugs – III
	Wed	25-Sep-24	Micro L-78 Viral Hepatitis MI 3.7	Clinical Posting			Lunch	Pharm L-129 PH1.30 Anti Arrhythmic - I	Path SGL-171&172 [CD] PA 34.4a Microscopy of skin Tumours; Pharm SGL-173&174[CD] Drugs affecting Bleeding and Thrombosis–II	
	Thu	26-Sep-24	Com Med SGT-24 Vaccination Types	Clinical Posting			Lunch	Path L-141 PA 28.2, Kidney – Renal Syndromes	Path SGL-173&174 [AB] PA 13.4 A Investigations of anaemia PCV / ESR; Pharm SGL-175&176 [CD] PH 1.42 General Principal of Chemotherapy	
	Fri	27-Sep-24	Path L-142 PA 28.3, Kidney - ARF	Clinical Posting			Lunch	Pharm L-130 PH1.30 Anti Arrhythmic - II	Micro SGL-137&138 [AB] Zoonotic diseases MI 8.1 Revision ; Pharm SGL-177&178 (CD) PH 1.19 (1,2,3,4) Anxiolytics	
	Sat	28-Sep-24	Pharm L-131 PH1.29 CHF -I [VI-IM]	Path L-143 PA 28.4:Kidney CRF	Micro SDL -10 STD MI 7.2	Pharm L-132 PH1.29 CHF -II	Lunch	Path L-144 PA 29.5 MGT-Prostatitis	Sports & Extra-Curricular Activities	
				SUNDAY						

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm	
Week 42	Mon	30-Sep-24	Pharm L-133 PH 1.17 L. A	Clinical Posting				Lunch	Micro L-79 Encephalitis a. MI 5.2 [VI-IM]	Micro SGL-139&140 [CD] Zoonotic diseases MI 8.1 Revision; Path SGL-175&176 [AB] PA2.3,2.5 Intracellular accumulations and pigments Revision	
	Tue	1-Oct-24	Path L-145 PA 29.3, MGT- Benign prostatic hyperplasia [VI-AN]	Clinical Posting				Lunch	Micro L-80 Encephalitis b. MI 5.2 [VI-IM]	Path L-146 PA-33.4: Paget's disease of the bone (SDL)	Pharm L-134 PH1.36 Diabetes mellitus
			Gandhi Jayanti: Wed 2 Oct 2024								
	Thu	3-Oct-24	Com Med SGT-25 Vaccination Adverse Effects [VI-MI]	Clinical Posting				Lunch	Path L-147 PA29.2: Carcinoma Penis	Path SGL-177&178[CD] PA 13.4 A Investigations of anaemia; Pharm SGL-179&180[AB] PH 1.42 General Principal of Chemotherapy	
	Fri	4-Oct-24	Path L-148 PA35.1 Meningitis including CSF findings [VI-IM] [HI-MI]	Clinical Posting				Lunch	Pharm L-135 PH 1.38 Corticosteroids	Micro SGL-141&142 [CD]:HIV, HCV, HBSAg Viral Markers MI 3.8-Revision; Pharm SGL- 181&182 (AB) PH 1.19 (1,2,3,4) Anxiolytics	
	Sat	5-Oct-24	Pharm L-136 PH1.36a I Parathyroid disorders & osteoporosis drugs	Path L-149 PA2.3,2.5: Intracellular accumulations & pigments	Micro L-81 Bone and Joint infection: MI 4.2	Pharm L-137 PH1.36b I Parathyroid disorders & osteoporosis drugs		Lunch	Path L-150 PA 25.6 Interpret LFT and viral hepatitis serology	Sports & Extra-Curricular Activities	
			SUNDAY								

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 43	Mon	7-Oct-24	Pharm L-138 PH1.16 Autacoids-I	Clinical Posting			Lunch	Micro L-82 UTI: MI 7.3	Micro SGL-143&144 [AB]:HIV, HCV, HBSAg Viral Markers MI 3.8-Revision; Path SGL-179&180 (CD) PA 2.4,2.5 Types of necrosis-Revision	
	Tue	8-Oct-24	Path L-151 PA 27.5 Ischemic heart disease-1	Clinical Posting			Lunch	Micro L-83 Meningitis MI 5.1	Path L-152 Seminar Heart disease-1	Pharm L-139 PH1.16 Autacoids-II
	Wed	9-Oct-24	Micro L-84 VRTI MI 6.1 -1	Clinical Posting			Lunch	Pharm L-141 PH1.16 Autacoids- IV	Path SGL-181&182[AB] PA 34.4 b Microscopy of skin Tumours ; Pharm SGL- 183&184 (CD) PH 1.19 (6,7,8,9,10) Sedatives & Hypnotics	
	Thu	10-Oct-24	Com Med SGT-26 Water Disinfection CM 3.2	Clinical Posting			Lunch	Path L-153 Seminar Heart disease-2 [VI-AN] [HI-IM]	Path SGL-183&184[CD]PA 34.4 b Microscopy of skin Tumours ; Pharm SGL- 185&186 (AB) PH 1.19 (6,7,8,9,10) Sedatives & Hypnotics	
	Fri	11-Oct-24	Path L-154 PA 23.3 Body fluids analysis-1	Clinical Posting			Lunch	Pharm L-142 PH1.16 Autacoids-V	Micro SGL-145&146 [CD] MI 3.4: Enteric fever; Pharm SGL- 187&188 [AB] PH1.19 (20,21,22,23,24,25,26) Anti- depressant -I	
				Dussehra: Sat, 12 Oct 2024						
			SUNDAY							

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 44	Mon	14-Oct-24	Pharm L-140 PH1.16 Autacoids-III	Clinical Posting			Lunch	Micro L-85 Zoonotic diseases MI 8.1	Micro SGL-147&148:(CD) Gram Staining ZN Staining & Stool routine Microscopy MI 1.2-Revision; Path SGL- 185&186(AB) PA 2.4,2.5 Types of necrosis-Revision	
	Tue	15-Oct-24	Path L-155 PA 2.5 Gangrenous intestine	Clinical Posting			Lunch	Micro L-86 Food, Air, Water Bacteria MI 8.8	Path L-156 PA.13.1, 13.3, 13.4 Introduction to haematology	Pharm L-143 PH1.16 Autacoids-VI
	Wed	16-Oct-24	Micro L-87 Genitourinary MI 7.1	Clinical Posting			Lunch	Pharm L-144 PH1.16 Autacoids- VII	Path SGL- 187&188[AB] PA 27.8 Interpret abnormalities in cardiac function testing in acute coronary syndromes; Pharm SGL-189&190 (CD) 1.19 (40,41,42,43,44,) Parkinsonism	
	Thu	17-Oct-24	Com Med SGT-27 Infectious disease epidemiology (selected definitions) CM 7.2	Clinical Posting			Lunch	Path L-157 PA5.1 a: Healing and repair	Path SGL-189&190 [CD] PA 27.8 Interpret abnormalities in cardiac function testing in acute coronary syndromes; Pharm SGL-191&192 (AB) PH 1.19 (40,41,42,43,44,) Parkinsonism	
	Fri	18-Oct-24	Path L-158 PA 6.1: Hemodynamic -Fluid and electrolyte balance, describe edema, its types	Clinical Posting			Lunch	Pharm L-145 PH1.16 Autacoids- VIII	Micro SGL-149&150 (AB) Gram Staining ZN Staining & Stool routine Microscopy MI 1.2-Revision; Pharm SGL- 193&194 (CD) PH 1.19 (27,28,29,30,31,32) anti-manics -I	
	Sat	19-Oct-24	Pharm L-146 PH1.16 Autacoids-IX	Path L-159 PA. 2.2, 2.3,2.4 Cell Injury and Adaptation	Micro L-88 Emerging infections MI 8.4	Pharm L-147 PH1.14(a)I Cholinergic drugs	Lunch	Path L-160 PA 9.1: Immunity – Principles and mechanism (SDL)	Sports & Extra-Curricular Activities	

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm	
Week 45			SUNDAY								
	Mon	21-Oct-24	Pharm L-148 PH1.14(a)II Cholinergic drugs	Clinical Posting			Lunch	Micro L-89 Choosing diagnostic Methods MI 8.13	Micro SGL-151&152 (AB) HIV:MI 2.7 Revision: Path SGL-191&192 (CD)PA 25.6 Interpret LFT and viral hepatitis serology panel		
	Tue	22-Oct-24	Path L-161 PA 17.1, 17.2 Hematology- Aplastic anemia	Clinical Posting			Lunch	Micro L-90 IOR MI 8.15	Path L-162 PA 16.3b Hematology – Sickle cell anemia	Pharm L-149 PH1.14(a)III Cholinergic drugs	
	Wed	23-Oct-24	Micro L-91 Identification of Bacteria MI 8.10	Clinical Posting			Lunch	Pharm L-150 PH1.14(a)I Anti- Cholinergic drugs	Path SGL-193&194[AB] PA 30.4, FGT- Ovarian Tumours, Gestational trophoblastic neoplasms; Pharm SGL- 195&196 (CD) PH 1.50: Immunomodulators (Seminar)		
	Thu	24-Oct-24	Com Med SGT-28 Screening: CM 7.6	Clinical Posting			Lunch	Path L-163 PA 18.2a Myeloid leukemia	Path SGL- 195&196 [CD] PA 30.4, FGT- Ovarian Tumours, Gestational trophoblastic neoplasms; Pharm SGL- 197&198 (AB) PH 1.50: Immunomodulators (Seminar)		
	Fri	25-Oct-24	Path L-164 PA– 9.1: Principles and mechanisms involved in immunity	Clinical Posting			Lunch	Pharm L-151 PH1.14(a)II Anti- Cholinergic drugs	Micro SGL-153&154:(CD) HIV:MI 2.7 Revision: Pharm SGL-199&200 (AB) PH 1.19 (27,28,29,30,31,32) anti-maniacs -I		
	Sat	26-Oct-24	Pharm L-152 PH 1.8 Drug interactions [VI-IM]	Path L-165 PA 18.2 b: Hematology – Lymphoid leukemia	Micro L-92 Zoonotic diseases MI 8.1	Pharm L-153 PH 1.24 Diuretics	Lunch	Path L-166 PA 11.1: Cytogenetic abnormalities and mutations	Sports & Extra-Curricular Activities		
				SUNDAY							

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm	
Week 46	Mon	28-Oct-24	Pharm L-154 PH 1.40 Infertility [VI-OG]	Clinical Posting				Lunch	Micro L-93 Anaemia MI 2.4	Micro SGL-155&156 (CD) Diagnostic method in infective endocarditis MI 2.3 -Revision; Path SGL-197&198 [AB] PA 25.6 Interpret LFT and viral hepatitis serology panel	
	Tue	29-Oct-24	PathL-167 PA 9.3: HLA system – Immune mechanism in transplant and transplant rejection [HI-MI]	Clinical Posting				Lunch	Micro L-94 Bone & Joint Infections MI4.2 [VI-OR]	Path L-168 PA 18.2 b: Hematology – Lymphoid leukemia	Pharm L-155 PH 5.2 Optimal Use of drugs
	Wed	30-Oct-24	Micro L-95 Opportunistic Infection: MI 8.2 [VISU,IM]	Clinical Posting				Lunch	Pharm L-156 PH 1.19 (37,38,39) Opioids	Path SGL-199 & 200 [AB] Fibroadenoma Breast; Pharm SGL-201&202 [CD]PH 1.19 (27,28,29,30,31,32) anti-manics -I	
			Diwali: Thurs, 31 Oct 2024								
	Fri	1-Nov-24	Path L-169 PA 3.1: Amyloidosis	Clinical Posting				Lunch	Pharm L-157 Principles of Pharmacology PH1.1(a)	Micro SGL-157&158 [AB] Diagnostic method in infective endocarditis MI 2.3 -Revision; Pharm SGL-203&204[CD] PH 1.51 Environmental pesticides, food adulterants (seminar)	
	Sat	2-Nov-24	Pharm L-158 Principles of Pharmacology PH1.1(b)	Path L-170 PA 19.4a: Non Hodgkin's lymphoma	Micro L-96 Genitourinary MI 7.1	Pharm L-159 1.37:Anterior Pituitary Hormones [VI-AN, PY]		Lunch	Path L-171 PA 20.1a Plasma cell myeloma	Sports & Extra-Curricular Activities	
			SUNDAY								

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm	
Week 47	Mon	4-Nov-24	Pharm L-160 PH 1.39: Contraceptives [VI-OG]	Clinical Posting				Lunch	Micro L-97 Interpretation of Results (Case Discussions) MI 8.15	Micro SGL-159&160 [AB] Skin & Soft tissue (P) MI 4.3; Path SGL-201&202 [CD] PA 25.1: Hepatobiliary system – Bilirubin metabolism, Jaundice	
	Tue	5-Nov-24	Path L-172 PA 19.4b: Hodgkin's disease	Clinical Posting				Lunch	Micro L-98 Infection Control PPE MI 8.7 [VI-SU]	Path L-173 PA 11.3a: Pathogenesis of common storage disorders in infancy and childhood	Pharm L-161 PH 1.36: Diabetes mellitus
	Wed	6-Nov-24	Micro L-99 Autoimmunity MI 1.10: Transplant & Cancer Immunology MI 1.11	Clinical Posting				Lunch	Pharm L-162 PH 1.49: Anticancer-Revision	Path SGL-203&204 [AB]Fibroadenoma Breast; Pharm SGL-205&206[CD]PH 1.51 Environmental pesticides, food adulterants (seminar)	
	Thu	7-Nov-24	Com Med SGT-29 Descriptive epidemiology, CM 7.5	Clinical Posting				Lunch	Path L-174 PA 26.2: Respiratory system- Lung abscess [VI-IM]	Path SGL-205&206 [CD]Fibroadenoma Breast; Pharm SGL-207&208[AB] PH 1.51 Environmental pesticides, food adulterants (seminar)	
	Fri	8-Nov-24	Path L-175 PA 21.2a: Vascular and platelet disorders including ITP [VI-IM]	Clinical Posting				Lunch	Pharm L-163 PH 1.34(1): Peptic ulcer -1 [VI-IM]	Micro SGL-161&162[CD] Skin & Soft tissue (P) MI 4.3; Pharm SGL- 209&210 [AB] PH 1.51 Environmental pesticides, food adulterants (seminar)	
	Sat	9-Nov-24	Pharm L-164 PH 1.57: Drugs for skin disorder- Revision	Path L-176 PA 11.2: Tumor and tumor like conditions in infancy and childhood	Micro L-100 Culture Media: MI 8.10;	Pharm L-165 PH 1.58: Drug (Ocular disorder)		Lunch	Path L-177 PA 10.2: Cysticercosis	Sports & Extra-Curricular Activities	
				SUNDAY							

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 48-49	Mon	11-Nov-24	Pharm L-166 PH 1.20:Alcohols [VI-IM]	Clinical Posting			Lunch	Micro L-101 Infective endocarditis MI 2.2	Micro SGL-163&164[CD] Interpretation of Results (Case Discussions) MI 8.15 : Path SGL-207&208 [AB] PA 25.1: Hepatobiliary system – Bilirubin metabolism, Jaundice	
	Tue	12-Nov-24	Path L-178 PA 7.1a:Neoplasia; benign neoplasm, [VI-IM,SU]	Clinical Posting			Lunch	Micro L-102 Drug Resistance & Antibiotic MI 1.6 [HI-PH]	Path L -179 PA 7.2a: Neoplasia – Molecular basis	Pharm L-167 PH 1.19 (20,21,22,23,2 4,25,26) Anti- depressant -I
	Wed	13-Nov-24	Micro L-103 VRTI MI 6.1 -2 [VI-IM]	Clinical Posting			Lunch	Pharm L-168 PH 1.44: Anti tubercular drugs	Path SGL-171&172 [AB] PA 27.8: Interpret abnormalities in cardiac function testing in acute coronary syndromes; Pharm SGL-211&212 (CD) PH 2.4 Posology in special Situation	
	Thu	14-Nov-24	Com Med SGT-30 Investigation of epidemic, CM 7.7 [VI-IM]	Clinical Posting			Lunch	Path SDL-12 PA 27.6a: CVS- Endocarditis [VI-IM]	Path SGL-173&174[CD]PA 27.8: Interpret abnormalities in cardiac function testing in acute coronary syndromes; Pharm SGL-213&214 (AB) PH 2.4 Posology in special Situation	
				Guru Nanak Jayanti: Fri, 15 Nov 2024						



NOIDA INTERNATIONAL INSTITUTE OF MEDICAL SCIENCES, GREATER NOIDA

Phase II TT for Batch 2022 w.e.f 18 December 2023

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
			16- 22 Nov-24; Sat to Fri: Preparatory Leave							
			23-Nov-24; Sat: Pre- Professional Examination Microbiology-I							
			24-Nov-24; Sun: Preparatory Leave							
Wk 50			25-Nov-24; Mon: Pre- Professional Examination Microbiology-II							
			26-Nov-24; Tue: Preparatory Leave							
			27-Nov-24; Wed: Pre- Professional Examination Pathology-I							
			28-Nov-24; Thurs: Preparatory Leave							
			29-Nov-24; Fri :Pre- Professional Examination Pathology-II							
			30-Nov-24; Sat : Preparatory Leave							
			1-Dec-24; Sun: Preparatory Leave							
			2-Dec-24; Mon: Preparatory Leave							
Week 51			3-Dec-24; Tue: Pre- Professional Examination Pharmacology-I							
			4-Dec-24; Wed: Preparatory Leave							
			5-Dec-24; Thu : Pre- Professional Examination Pharmacology-II							
			6-Dec-24; Fri : Pre-Professional Practical's-1							
			7-Dec-24; Sat : Pre-Professional Practical's-2							
			8-Dec-24; Sun: Preparatory Leave							
			9-Dec-24; Mon: Pre-Professional Practical's-3							
Week 52			10-Dec-24; Tue : Pre-Professional Practical's-4							
			11-Dec-24; Wed: Pre-Professional Practical's-5							

Wk	Dy	Dt	9-10am	10- 11 am	11- 12 Noon	12 Noon-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Week 53			12-18 Dec-24; Thurs to Wed: Preparatory Leave							
			19-Dec-24; Thurs: Final Professional Examination Microbiology-I							
			20-Dec-24; Fri: Preparatory Leave							
			21-Dec-24; Sat: Final Professional Examination Microbiology-II							
			22-Dec-24; Sun : Preparatory Leave							
Week 54			23-Dec-24; Mon: Preparatory Leave							
			24-Dec-24; Tue: Final Professional Examination Pathology-I							
			Christmas Day Mon 25 Dec 2024							
			26-Dec-24; Thu: Final Professional Examination Pathology-II							
			27-Dec-24; Fri: Preparatory Leave							
			28-Dec-24; Sat: Final Professional Examination Pharmacology-I							
			29-Dec-24; Sun: Preparatory Leave							
Week 55			30-Dec-24; Mon: Final Professional Examination Pharmacology-II							
			31-Dec-24 to 4-Jan-25; Tues to Sat: Final Professional Practical's							

VI- Vertical Integration; **HI-** Horizontal Integration; **SDL-**Self Directed Learning; **AITO** –Alignment Integration Topics

Phase II (Batch 2022) Examinations Dates

Exams	Theory Dates	Practical Dates
Term-I	22-25 Apr'24	26-30 Apr'24
Term-II	12-14 Aug'24	16-20 Aug'24
Pre-Professional	23 Nov-5 Dec'24	6-11 Dec'24
Professional	19-30 Dec'24	31 Dec'24-4 Jan'25